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Abstract 
Therapeutic strategies of stroke can take two directions: to prevent brain 
damage from stroke or aid in its repair after a stroke. In this thesis, a rat stroke model, 
which mimics the human small vessel stroke, was used. Two potential repair 
strategies were investigated with this model, reduction of inflammatory processes 
with the aid of minocycline treatment and replacing necrotic neurons with new ones 
with the aid of neurogenesis of endogenous progenitor cells.  
The stroke model is induced by disrupting the medium-size pial vessels within 
a 5mm-circular brain surface of adult Wistar rats. This leads to a cone-shaped cortical 
lesion. Therefore it mimics the clinical situation of lacunar infarction, the most 
frequent outcome of small vessel stroke.  
Minocycline, a second-generation tetracycline, prevented cavitation a n d  
facilitated the repopulation of the lesion by reactive astrocytes. However, I could not 
identify the molecular target as the number of activated microglia, infiltrating 
leukocytes and CD3+ lymphocytes as well as interleukin-1β expression were not  
significantly altered.  
Doublecortin (DCX) is a microtubule-associated protein expressed by 
migrating neuroblasts and immature neurons. After injury, DCX-positive cells 
appeared in the neocortex at the base of the lesion. These cells exhibit a morphology 
resembling differentiated post-migratory neurons with long branched processes. 
Some of the DCX-positive cells were also immunoreactive for βIII-tubulin, another 
marker of immature neurons. This might indicate a migratory pathway for developing 
neuroblasts from the subventricular zone (SVZ) through the corpus callosum to the 
lesion. SVZ cells were labeled with carboxyfluorescein diacetate, succinimidyl ester 
(CFSE) stereotaxical injections. Although rostral migratory stream and olfactory bulb 
were intensely labeled, no CFSE containing cells were found in the cortex underneath 
the lesion. These results suggest that the DCX-positive cells may not originate from 
neural precursors from the SVZ, but might be generated from local progenitor cells.  
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In summary, using the PVD II model, which mimics the lacunar stroke, I 
found that neuroblasts appeared spontaneously near the lesion in the cerebral cortex 
and were attempting to upregulate neuronal properties. Reducing inflammation with 
post-stroke minocycline treatment prevented cavitation. I think both findings open up 
exciting new avenues for treatment of lacunar infarctions. 
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1. GENERAL INTRODUCTION  
1.1 Stroke 
Stroke is a leading cause of mortality and morbidity as well as a major 
component of health costs in most countries. In Canada alone, around 40,000 to 50,000 
strokes and 16,000 stroke-related deaths occur each year with an annual economic cost 
of around $2.7 billion. Approximately 20% of stroke patients do not survive the first 
month after a stroke. Another 30% will survive for at least six months, but will be 
permanently dependent on others. Although a stroke can and does occur in infants and 
children, it mainly affects adults in the middle and later years of life. Stroke is therefore 
a major cause of prolonged neurological disability in adults (Warlow et al., 2003). The 
incidence of stroke-related deaths is predicted to double by 2030 in the USA due to the 
aging of the population (Frizzell, 2005). This highlights the significance and importance 
of stroke prevention and treatment.  
Stroke is defined by the World Health Organization as a clinical syndrome of 
rapid onset of a cerebral deficit, lasting more than 24 h or leading to death, with no 
apparent cause other than a vascular one (Fatahzadeh and Glick, 2006). In humans, 
stroke is a diverse disease in terms of causes, manifestations, and anatomic sites. 
Depending on the underlying pathogenesis, strokes are subclassified into ischemic and 
hemorrhagic types. Approximately 15% of all strokes are hemorrhagic in nature. These 
are caused by either the rupture of an artery deep within the brain (hemorrhagic stroke, 
intracerebral hemorrhage), bleeding on the brain surface or bleeding between the brain 
and the skull (subarachnoid hemorrhage) as a result of trauma or from the rupture of an 
aneurysm. Approximately 85% of all strokes are classified as cerebral ischemia and 
result from occlusions of large or small arteries. They may be caused by either 
atherosclerotic thrombi (thrombus) or distant emboli (embolism) (Fatahzadeh and Glick, 
2006). 
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Ischemic stroke can occur in a discrete area of the brain (focal ischemia) or in the 
whole brain (global ischemia) (Back et al., 2004). Global ischemia occurs when there is 
an interruption of blood flow or severe hypoxia to the entire brain. Such situations are 
mostly caused by cardiac arrest, shock, near drowning or severe systemic hypotension.  
It seems that different brain regions have different thresholds for ischemia and certain 
neuronal populations within an individual are selectively vulnerable to ischemia. For 
instance, white matter is more resilient than gray matter and hippocampal CA1 
pyramidal cell neurons are very vulnerable to relatively brief periods of ischemia (Kirino 
and Sano, 1984; Back et al., 2004). 
Focal cerebral ischemia affects restricted brain regions and will impair the 
function of such areas. In clinical settings, focal ischemia happens more frequently than 
global ischemia. Regardless of the etiology, the clinical presentation of symptoms 
depends largely upon the location of the occluded vessels and the presence of collateral 
circulation (Felberg and Naidech, 2003; Fatahzadeh and Glick, 2006). The symptoms 
are often transient if the occlusion occurs at one of the small intracerebral vessels. The 
condition is referred to as lacunar stroke (Frizzell, 2005; Fatahzadeh and Glick, 2006). 
Around 20% of ischemic strokes are lacunar strokes. Lacunar infarcts are commonly 
found in the putamen, caudate, thalamus, pons, internal capsule and cerebral white 
matter, in descending order of frequency (Bamford et al., 1987; Arboix and 
Marti-Vilalta, 2004). In contrast, large vessel stroke is characterized by extensive 
cerebral infarction and results from occlusion of a major intracranial vessel.  
Frequently, high level brain functions are affected and the prognosis is poor.  
Unlike global ischemia, which leads to neuronal cell death in vulnerable areas of 
the brain, focal ischemia produces usually one distinct mass of damaged brain tissue 
termed infarct. The central region supplied by the affected artery is known as the infarct 
core, and is often the region with the highest impairment of blood flow. The surrounding 
area is called the penumbra, often spared from major ischemia impact by the collateral 
circulation from other arteries. In animal models of middle cerebral artery occlusion 
[MCAO], the cerebral blood flow within the core decreases to less than 15% of the 
baseline, whereas the flow in the penumbra is less than 40%. If the blood flow in the 
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penumbral zone further decreases, the infarct area will inevitably expand (Dirnagl et al., 
1999; Hossmann, 2006).  
Because the severity and reversibility of the ischemic damage depend on the 
degree of the flow reduction, there are major physiologic differences between the core 
and penumbra. Therefore in cerebral ischemia the pathophysiology of core and 
penumbra differs extensively. The ischemic core, which is subject to the most severe 
flow reduction, undergoes irreversible damage in a relatively short period of time. In 
contrast, the ischemic penumbra experiences disturbances of neuronal function that are 
at least initially reversible. The ischemic penumbra can be “rescued” from infarction if 
flow is restored or if neuroprotective measures are undertaken. The ischemic penumbra, 
therefore, is the major target of neuroprotective strategies (Fisher and Garcia, 1996; 
Hossmann, 2006).  
Over the past decades, substantial progress has been made in understanding the 
pathophysiologic mechanisms of stroke. However, currently only thrombolytic therapy 
within a narrow time window after stroke onset (Small et al., 1999; Frizzell, 2005) is 
accepted as a therapeutic option for ischemic stroke. Aspirin, other antiplatelet agents, or 
anticoagulants are used as preventative therapy for embolic stroke patients (Felberg and 
Naidech, 2003). Understanding the pathophysiology of brain ischemia is necessary to 
develop potential therapies for ischemic stroke. In t h is chapter, the cellular and 
molecular events leading to brain damage after experimental focal cerebral ischemia are 
reviewed as well as the therapeutic strategies. The main focus is on possible therapeutic 
targets based on n e w  discoveries in neuroinflammation and intrinsic regenerative 
mechanisms of the brain. This chapter is necessarily limited to focal ischemia, as this is 
the stroke type most often investigated with animal models and it has clinical relevance 
due to its high prevalence.  
1.2 Pathophysiology of Focal Cerebral Ischemia 
1.2.1 Overview of the Mechanisms  
The current understanding of stroke pathophysiology extends far beyond the 
immediate effects of the initial impairment of local blood circulation. The events that 
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take place in the ischemic area are complex and follow a stereotypic temporal and 
spatial pattern. As the brain has a very high demand for oxygen and glucose, within 
minutes of cessation of blood flow, brain tissue is deprived of glucose and oxygen and 
the acidic byproducts of metabolism accumulate, which results in a rapid decline in ATP 
concentration. The energy deficiency results in failure of the Na+/K+-ATPase. The 
resulting loss of ionic gradients leads to depolarization. The rapidity with which this 
depolarization occurs depends on the severity and duration of ischemia. Shortly after the 
onset of ischemia, glutamate is released into extracellular compartments and it activates 
postsynaptic glutamate receptors, such as ligand-gated ionotropic (NMDA, AMPA) and 
G-coupled metabotropic (mGluR) receptors. This leads to accumulation of intracellular 
Ca2+ a n d  an increase in intracellular Na+ and Cl- concentrations. This massive 
disturbance of ion homeostasis will eventually lead to cell lysis and cytotoxic edema. 
The energy failure is probably the predominant mechanism of cell death in the ischemic 
core (Siesjo, 1992a; Dirnagl et al., 1999; Smith, 2004). 
In the penumbra, where the blood flow reduction is not sufficient to cause rapid 
energy failure, other mechanisms, such as glutamate excitotoxicity, calcium overload 
and free radical damage, might play major roles. Excessive extracellular glutamate and 
potassium may diffuse from the core into the penumbral areas and trigger peri- infarct 
depolarization, which contributes to the expansion of the lesion from the core into the 
penumbra. Elevated amounts of intracellular Ca2+ retard mitochondrial function and 
cause formation of toxic metabolites, such as proteases, phospholipases, cytochrome 
oxidase and free radicals. The latter trigger an intracellular ‘death’ cascade. In addition 
there is secondary injury as a result of inflammation (Siesjo, 1992a; Dirnagl et al., 1999; 
Smith, 2004; Hossmann, 2006).  
1.2.2 Neuronal Cell Death after Focal Ischemia 
Hypoxic neurons die by two different modes: necrosis and apoptosis. Necrotic 
cell death is more common with more extreme levels of ischemia, whereas apoptotic cell 
death is more common with less severe insults. Thus, the core tissue of an infarct dies a 
necrotic death, and, depending on the location within the penumbra, cells die by means 
of either mode, with apoptosis more common in cells further away from the core.  
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Necrosis is not an energy-consuming process and is independent of protein synthesis. It 
is characterized by membrane dysfunction and cell swelling.  I t  usually induces an 
inflammatory response. In contrast, apoptosis is an energy-dependent programmed cell 
death (Choi, 1996). The cell requires active gene transcription and protein synthesis to 
degrade its own DNA. The morphologic features of apoptotic cell death are quite 
different from necrotic cell death, with DNA laddering and regular clumping of 
chromatin (apoptotic bodies). Apoptosis is characterized morphologically by primary 
changes in the nuclei, such as early extensive chromatin condensation, marginalization 
and segregation followed by fragmentation, whereas the cell membrane and 
mitochondrial structure are relatively preserved (Snider et al., 1999). In the final stages 
of cellular dissolution, apoptotic bodies may be formed by cellular fragmentation into 
spherical vesicles. This is followed by a stereotypical loss of cellular architecture that 
involves the activity of caspases and other enzyme systems. This process may take 
several days. This DNA fragmentation can be detected in situ in tissue sections by 
positive terminal deoxyribonucleotide transferase (TNT)-mediated dUTP nick end 
labeling (TUNEL) (Namura et al., 1998; Ferrer and Planas, 2003).  
In experimental rat models of transient focal ischemia, apoptotic neurons were 
located mainly in the inner boundary zone of infarcts, increasing in number as early as 
0.5 h, peaking at 24-48 h, and persisting for 4 weeks after the onset of reperfusion (Li et 
al., 1995a; Li et al., 1995b). Similar results were described in an ischemic model 
employing photothrombosis (Braun et al., 1996). Many TUNEL-positive cells were 
found within the infarct region from 12 h to 3 days. By day 6 they were preferentially 
located in the boundary zone of the infarct, and by day 14 they had disappeared. A high 
proportion of TUNEL-positive cells were identified as apoptotic neurons by their 
morphology. Infiltrating neutrophils were found to be in close contact with apoptotic 
neurons, which suggests a role for leukocytes in the development of apoptotic neuronal 
cell death (Li et al., 1995b; Braun et al., 1996). Taken together, these studies point to 
neuronal death in cerebral ischemia as a prolonged process that involves apoptotic 
mechanisms. Apoptosis could contribute t o  the expansion of the primary ischemic 
region into the periphery. This would explain the dynamics of penumbra evolution 
(Love, 2003; Smith, 2004).  
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Apoptosis is characterized by a biochemical cascade which leads to the 
activation of caspases, a family of proteases that  exist as inactivate proenzyme 
(procaspase) precursor proteins in cells. Once they are cleaved, the active enzymes 
cleave other proteins, including structural cytoskeletal proteins such as actin and  
gelsolin, structural nuclear proteins such as lamins, and DNA repair proteins such as the 
DNA-repairing enzyme PARP and the anti-apoptotic protein Bcl-2 and Bcl-xL.. This in 
turn leads to the apoptotic cleavage of nuclear DNA. Caspases 1, 3, 8 and 9 are involved 
in cerebral ischemia. Caspase 1, also known as interleukin-1 converting enzyme, is 
involved in the maturation of cytokines and the induction of inflammation. Caspases 3, 8 
and 9 are directly involved in apoptosis. There are two pathways of caspase activation: 
death receptor-mediated (extrinsic) and mitochondrial (intrinsic). The extrinsic pathway 
starts with the activation of the death receptor. The principal death receptor in cerebral 
ischemia is Fas. Its activation induces stimulation of a death- inducing signaling complex 
(DISC) that causes caspase 8 activation, leading to the recruitment of other caspases and 
activation of the intrinsic apoptotic pathway.  In the intrinsic pathway, cytochrome C is 
released from the mitochondrial membrane and then in turn activates downstream 
caspases 3, 6 and 7, of which caspase 3 acts as a final common pathway. It is responsible 
for inactivating PARP, thus disabling DNA repair mechanisms. The result is cellular 
death. Cytochrome C is a member of the mitochondrial electron-transport chain which is 
required for the generation of ATP. It is not only essential for energy production, but it 
is also a central mediator in the caspase activation cascade. Once it is released from the 
mitochondria into the cytoplasm, it binds to apoptotic protease activating factor 1 
(Apaf-1) and forms the apoptosome together with ATP and procaspase 9 .  The 
apoptosome activates caspase 9 and leads to sequential activation of downstream 
caspases. The balance between pro-apoptotic (Bid, Bax, Bad, Bag) and anti-apoptotic 
(Bcl-2, Bcl-xL) proteins  i n  the Bcl-2 family plays a crucial role in the release of 
cytochrome C (Snider et al., 1999; Ferrer and Planas, 2003; Friedlander, 2003; Love, 
2003; Sugawara et al., 2004).  
A large body of evidence shows that brain ischemia causes activation of 
caspases.  Up-regulation and activation of caspases have been observed to precede the 
death of neurons in models of transient focal ischemia (Namura et al., 1998; Hermann et 
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al., 2001), permanent focal ischemia (Velier et al., 1999; Sasaki et al., 2000; Harrison et 
al., 2001) and global ischemia (Ni et al., 1998; Ouyang et al., 1999).  
1.2.3 Gliosis in Focal Ischemia  
In histological analysis, infarction is characterized by pannecrosis of neurons and 
glial cells. Within the first few hours after injury, not only neurons but also all the glial 
and vascular cells in the infarct core area undergo cell death, as reviewed in the previous 
section. At the same time, brain damage initiates a series of cellular and molecular 
events that evolve over several days. The main cell types involved in these changes are 
astrocytes, microglia, and oligodendrocyte precursors, with some involvement of 
meningeal cells if the injury penetrates the meninges. In addition, neural stem cells 
and/or neural progenitors may be involved. Macrophages from the bloodstream and 
microglia migrate into the injured area from the surrounding tissue within hours of 
injury. After several days, large numbers of oligodendrocyte precursors are recruited. 
With time, these cells decrease in number, and the injury area is surrounded by reactive 
astrocytes. This process is called reactive gliosis or glial scarring (Fawcett and Asher, 
1999). 
1.2.3.1 Astrocytes 
Astrocytes are the principal macroglial cells in the CNS and make up about 50% 
of human brain volume. They participate in regulation of microvasculature, maintenance 
of ionic homeostasis and control of neuronal transmission. They also play an important 
role in the plasticity after injury. Accordingly, they are essential for normal neuronal 
activity, critically influence neuronal survival during ischemia and participate in repair 
and regeneration in the post- injury period (Walz and Juurlink, 2002). 
Within the ischemic lesion, astrocytes exhibit swelling, fragmentation of 
processes and disintegration at the same time as or before neuronal changes. 
Subsequently, expression of the astrocytic marker glial fibrillary acidic protein (GFAP) 
is decreased and barely detectable anymore (Chen et al., 1993). However, starting 4-6 h 
after ischemia, the astrocytes surrounding the area of ischemia become reactive. This 
activation is characterized by hypertrophy and/or proliferation. The response is enhanced 
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by the migration of microglia and macrophages to the damaged area. Astrocytes 
activated by injury change shape by enlarging their cell bodies and extending m a ny 
processes. These processes tightly interweave and are bound together by gap junctions. 
One major change of reactive astrocytes is the up -regulation of their intermediate 
filaments, which is directly associated with morphological changes (Stoll et al., 1998). 
In both the MCAO and cortical photothrombosis ischemia models, the number and 
intensity of reactive astrocytes at the lesion site steadily increase over approximately 1 
week (Inuzuka et al., 1996; Yamashita et al., 1996). Some of these cells co-express other 
intermediate filament proteins, such as vimentin and/or nestin, which are normally found 
in immature astrocytes (Ridet et al., 1997). At later times after ischemia, reactive 
astrocytes in the immediate vicinity of the injury interweave their processes to form a 
barrier, termed the glia limitans, which consists mainly of a tightly packed meshwork of 
astrocytic processes and a large amount of ECM in a limited extracellular space.  
The function of the glia limitans is to insulate the brain parenchyma from the 
non-brain compartments, replacing the destroyed blood brain barrier (BBB) or  the pia 
mater. Although its functional role is not completely understood, this can be considered 
as a response by the b r a in  to prevent further spread of damage and to restore 
homeostasis through isolation of the damaged region. However, glial scar formation has 
also been regarded as the major impediment to axonal regeneration and CNS repair 
(Ridet et al., 1997; Sofroniew, 2005). GFAP-knockout mice or mice treated with GFAP 
antisense RNA show enhanced expression of laminin and become more permissive to 
neurite growth (Sofroniew et al., 1999; Costa et al., 2002). This suggests that  
cytoskeletal proteins may contribute to the barrier effect of the glial scar for axonal 
extension. In addition reactive astrocytes secrete collagens and sulfate proteoglycans 
which also impede neurite growth (Fidler et al., 1999; Liesi and Kauppila, 2002). Recent 
studies suggest that astrocytes are involved in guiding axons and newly generated 
neurons and that they have trophic effects on neurite outgrowth and neurogenesis (Chen 
and Swanson, 2003). This appears to contradict the previous view. Reactive astrocytes 
increase the expression of several growth factors, such as basic fibroblast growth factor 
(bFGF), brain-derived neurotrophic factor (BDNF) and neuregulins, which are know to 
stimulate neurite outgrowth (Ridet et al., 1997; Tokita et al., 2001). In vitro studies show 
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that astrocytes induce neurogenesis in adult neural stem cells in culture (Song et al., 
2002). The recent discovery of neurogenesis triggered by focal ischemia suggests that 
reactive astrocytes might be essential in neuronal differentiation processes.  
Although astrocytes have a reputation for providing trophic support for neurons, 
recent studies have shown that they participate in the inflammatory response after 
ischemia. Activated astrocytes can express the inducible form of nitric oxygen synthase 
(iNOS) within a few hours and up to 3 days after ischemia in the rat (Iadecola et al., 
1995). iNOS activates nitric oxide, a reactive oxygen species that contributes to neuronal 
cell death (Hewett et al., 1994). Reactive astrocytes also have the capability to produce 
various proinflammatory cytokines, such as IL-1ß, TNF-α, interferon, highly cytolytic 
proteins, complement proteins and prostaglandins (Chen and Swanson, 2003; Panickar 
and Norenberg, 2005). Furthermore, there are also reports that astrocytes are capable of 
phagocytosis (Aloisi, 1999). Therefore, astrocytes play a major role in the 
neuroinflammatory cascade and contribute to the neuronal damage in cerebral ischemia.  
1.2.3.2 Microglia / Macrophages  
Microglia are resident brain macrophages that are derived from the monocytic 
lineage. In the normal adult brain, they are in a quiescent state showing a typical 
ramified morphology with short branched processes and expressing few surface 
molecules. Rapid activation of glial cells occurs prior to any obvious signs of neuronal 
death. Microglia activate at a very early stage in response to CNS injury. After 
activation, they exert multiple functions by transforming into phagocytes. The initial 
activation is characterized by morphological changes, involving enlarged cell bodies and 
contraction of processes, as well as up-regulation of the surface molecules isolectin-B4, 
complement type 3 receptor (CR3, CD11b/CD18 complex), and microglial response 
factor-1 (MRF-1). In this partially activated state, microglia proliferate and migrate to 
the sites of injury, but they are not phagocytic and do not produce cytotoxic molecules. 
In the presence of dying neurons, microglia become further activated and at this stage, 
they are true phagocytes with amoeboid morphology. They express the same markers as 
the cells of the peripheral macrophage lineage, including MHC class I, MHC class II, 
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leukocyte common antigen (LCA) and CD4. In this state they are virtually 
indistinguishable from blood-borne macrophages (Kreutzberg, 1996; Streit et al., 1999). 
In transient MCAO, by day 1, activated microglia are found in the penumbra 
close to the neurons, their processes often encircling the neurons. The entire infarct area 
is covered by round and amoeboid macrophages within 3 days after MCAO induction. 
Within 4 weeks, the debris was completely cleared by these phagocytes (Kato et al., 
1996; Lehrmann et al., 1997; Zhang et al., 1997). In fact, these macrophages contain two 
different pools, activated microglia and blood-borne monocytes/macrophages. 
Monocytes/macrophages infiltrating from the blood stream into an ischemic area are 
recruited with a delay in comparison with resident microglia/macrophages (Schroeter et 
al., 1997).  
The overall role of microglia, whether it is beneficial or detrimental in cerebral 
ischemia, is not clear at present. Activated microglia/macrophages produce toxic 
molecules such as nitric oxide (NO), oxygen radicals, arachidonic acid derivatives, 
chemokines and cytokines. In particular, proinflammatory cytokines such as TNFα, 
IL-1, and IL-6 play important roles as mediators of the inflammatory phase of cerebral 
ischemia. In vitro studies suggest that microglia kill neurons by secreting NO, oxygen 
free radicals, glutamate, and other cytotoxic substances (Farber and Kettenmann, 2005). 
On the other hand, in areas of severe damage, microglia can phagocytose debris and 
attack microorganisms that may infect the damaged area. In addition, microglia produce 
neurotrophins in vitro, as well as TGF-ß and plasminogen, which are involved in tissue 
repair and neurite outgrowth (Streit, 2002). Thus, it is very likely that microglia play 
different roles at different time points: amplifying the effects of neuroinflammation and 
mediating cellular degeneration in the brain as well as protecting the CNS, with these 
protective or regenerative activities occurring days or even weeks after the onset of 
ischemia (Streit et al., 1999; Streit, 2002).  
1.2.3.3 Neutrophils and Macrophages 
Circulating leukocytes invade and contribute to the developing infarction 
(Tomita and Fukuuchi, 1996). In response to an injury, the resident inflammatory brain 
cells, microglia, are activated and lead to local generation of various cytokines. These in 
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turn act on the endothelial cells lining the local blood vessels, induce an increased BBB 
permeability and start expressing various adhesion molecules. These events trigger a 
roll-on of circulating leukocytes.  They adhere to endothelial cells, and eventually 
transmigrate into the damaged cerebral parenchyma. Various leukocyte subpopulations 
are recruited at different times (Stoll et al., 1998). Neutrophils are the first 
hematogenous leukocytes that appear in the brain in response to focal ischemia, 
followed by monocytes/macrophages and some lymphocytes. Monocytes/macrophages 
are the most abundant leukocytes that enter the brain after focal ischemia. After transient 
MCAO in rats, neutrophils can be detected in microvessels of the ischemic hemisphere 
as early as 30 min after the occlusion with a peak at 12 h, whereas intraparenchymal 
neutrophils are most numerous at 24 h and decline rapidly thereafter. Lymphocytes can 
be found accumulating in the border zone of an infarct by day 1, peaking by day 3 in the 
photothrombosis and permanent MCAO models in rats (Schroeter et al., 1994; Jander et 
al., 1998). Blood-borne monocytes/macrophages arrive at the ischemic zone together 
with the lymphocytes, but persist up to day 14 (Jander et al., 1998). The accumulation of 
these microvasular leukocytes was originally believed to contribute to local debris 
removal and scar formation in the infarcted area. However, recent studies show that 
these cells generate and release highly reactive oxygen species (free radicals) (Huang et 
al., 2006). Their toxic enzymes such as myeloperoxidase have been shown to degrade 
components of the basal lamina and to contribute to the neuroinflammatory response. As 
well they directly release inflammatory mediators, such as IL-1ß, TNF-α and CINC, 
which contribute to irreversible infarction (Huang et al., 2006).  
In summary, brain ischemia produces a well-defined gliotic response, which 
involves several cell types. The activation, proliferation and hypertrophy of these cells 
are the hallmark of this reaction. The primary goal of this response is to destroy and 
clear up damaged cells, tissue and foreign substances, to mediate repair by restoring 
blood supply, re-establishing the integrity of the blood-brain barrier and promoting 
homeostasis in and around the injury. However, activated microglia / macrophages, 
neutrophils, and astrocytes can release many toxic substances, such as cytokines. They 
contribute to the disruption of the BBB and the resulting edema, and release cytokines, 
which contribute to the inflammation and secondary damage following brain ischemia 
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(Barone and Feuerstein 1999). Indeed, it seems there is a close relationship between 
inflammation and gliosis since gliosis can be induced by cytokines (Barone and 
Feuerstein 1999). Activated glial cells then secrete cytokines, which in turn contribute to 
CNS inflammation and gliosis.   
1.3 Potential Treatments for Stroke Therapy  
In the past, neuroprotection has been the only goal of basic scientists and clinical 
investigators. Neuroprotection, a therapeutic intervention, is designed to target the acute 
events triggered by focal perfusion deficits in the brain. This strategy would reduce the 
volume of cerebral infarction, which would in turn reduce functional deficits. However, 
the recent discov e r y  o f  neural stem cells/multipotent precursors and continuous 
neurogenesis in the adult brain, has revolutionized the view of brain plasticity and has 
suggested new therapeutic strategies for degenerative CNS disorders and cerebral 
ischemia. From a therapeutic point of view, the recruitment of adult intrinsic stem cells 
for structural brain repair or the activation and expansion of isolated adult stem cells will 
be of great importance. Therefore, current experimental studies of stroke therapy in 
animals have focused on two aspects:  
1. Neuroprotection: targeting the acute events triggered by the focal perfusion 
deficits in brain, to reduce brain damage and create a better outcome (Romero et al., 
2006). 
2. Regeneration: targeting the chronic events and aspects of neuronal plasticity 
and regeneration to improve recovery (Smith, 2004).  
1.3.1 Targeting Neuroprotection to Improve Outcome  
 With the better understanding of the complex cascade of brain damage after 
ischemia, a greater number of neuroprotective interventions targeting different 
pathological elements have been tested and developed in animal models of stroke. These 
various interventions include calcium channel blockers, anti-excitotoxic substances 
(such as a variety of glutamate receptor antagonists), free radical scavengers, 
anti-apoptotic drugs and anti- inflammatory agents (Liebeskind and Kasner, 2001; Turley 
et al., 2005). Unfortunately, clinical trials for most of these approaches have not proven 
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safe or did not show improved stroke outcomes, despite repeated successes in animal 
trials. One of the possible causes for this discrepancy between the animal studies and 
clinical tests is that the windows for the treatment were set too late to target the desired 
molecular pathways (Hossmann, 2006). For instance, the increased glutamate level after 
injury lasts only for 10-30 min and most of the damage related to its excitoxicity may 
occur within the first 60 min (Ikonomidou and Turski, 2002). After that, glutamate may 
serve in a neuroprotective and a regenerative function (Ikonomidou and Turski, 2002). 
Calcium levels plateau within minutes of the onset of damage, and in most of the animal 
studies, calcium channel blockade was started within 1 hour of ischemic onset (Horn and 
Limburg, 2001).  Therefore, by the time patients are available for treatment damage 
caused by these mechanisms might be largely completed.  
Unlike these early events leading to damage, post-ischemic inflammation 
evolves within hours and lasts for several days. It is a dynamic process, potentially 
providing a longer therapeutic window. Immediate early response genes are expressed 
within 2 h and inflammatory cytokines, chemokines and adhesion molecules are 
produced, inducing the leukocyte accumulation and migration as well as microglia 
activation (Hossmann, 2006). Glia scarring and tissue remodeling are followed and 
associated with healing of infarct tissue. As an essential component of pathological 
mechanisms responsible for ischemic stroke, inflammation may also contribute to the 
secondary brain damage following ischemia, as well as being a potential cause for the 
exacerbation of ischemic brain injury. In addition, inflammatory mechanisms are not 
fundamental for physiological brain functions. Thus interference with these secondary 
responses may not result in intolerable side effects (Barone and Feuerstein, 1999). 
Therefore, post–ischemic inflammation is a promising target for therapeutic intervention 
in ischemic stroke. The inflammation reaction is an attractive pharmacologic 
opportunity, considering its rapid initiation and progression over many hours after stroke 
and its contribution to the evolution of tissue injury. Therefore, inflammation provides a 
much longer therapeutic window and it is more practical to design effective therapeutic 
interventions targeting the inflammation pathway.  O ne might  therefore expect a 
reasonable probability for this intervention to be successful in the treatment of the stroke 
patient. Since the cellular components of inflammation have already been reviewed in 
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the gliosis section, the major molecular elements that trigger and promulgate 
inflammatory signals will now be reviewed, since these signals may provide the targets 
for therapeutic intervention. Experimental attempts have explored the possible beneficial 
effects of pharmacologic manipulation of certain inflammatory elements. The effects of 
minocycline, an antibiotic exhibiting an anti- inflammatory ability in CNS injury and 
experimental ischemic models, will also be reviewed.  
1.3.1.1 Brain Inflammatory Response to  Ischemia: a Potential Therapeutic 
Opportunity  
Focal cerebral ischemia causes a strong inflammatory response involving a 
complex set of interactions between vascular structures and inflammatory cells (Stoll et 
al., 1998). The vascular endothelium promotes inflammation through the up-regulation 
of adhesion molecules such as ICAM, E-selectin, and P-selectin that bind to circulating 
leukocytes and facilitate their migration into the CNS. At the same time, 
pro-inflammatory cytokines act directly on endothelial cells causing increased BBB 
permeability and activation of intracellular adhesion molecules, such as ICAM-1, 
P-selectin, and  E -selectin ( Danton and Dietrich, 2003). This helps the circulating 
leukocytes migrate into the damaged tissue. These peripheral inflammatory cells include 
neutrophils, T- lymphocytes and mononuclear phagocytes. Microglia, the resident brain 
inflammatory cells (reviewed in the gliosis section), are activated early in response to 
ischemic insults, producing pro- inflammatory cytokines (Danton and Dietrich, 2003; 
Huang et al., 2006). 
Post-ischemic inflammation exerts its influence primarily through a complex 
cytokine network. Often cytokines are divided into pro- and anti- inflammatory 
mediators based on their ability to promote or suppress immunoactivation. Among them, 
IL-1ß and TNF-α are the most important and well-studied in mediating the inflammatory 
reaction. It has been shown in the CNS that activated microglia are the primary cells to 
produce and release IL-1ß and TNF-α (Arvin et al., 1996; del Zoppo et al., 2000). 
Neurons, astrocytes and endothelial cells also produce these cytokines (Wang and 
Shuaib, 2002). Increased IL-1ß and TNFα mRNA and protein levels have been found in 
both focal and global ischemia (Wang and Shuaib, 2002). IL-1ß and TNF-α are involved 
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in different aspects of post- ischemic inflammation. IL-1ß can induce gene expression of 
phospholipases A2, iNOS and cyclooxygenase-2 (COX2), which leads to the production 
of the potent pro- inflammatory mediators prostaglandins (PG) and NO, thus furthering 
the neuroinflammatory cascade (Wang and Shuaib, 2002). TNF-α has been shown to 
increase BBB permeability and facilitate the entry of peripheral inflammatory cells into 
the brain (Pan et al., 1997) and may also contribute to the prolonged activation of 
microglia in an autocrine fashion (Kuno et al., 2005).  
Recent studies have shown that several transcription factors, such as nuclear 
factor (NF-κB), hypoxia- inducible factor-1 (HIF-1), interferon regulatory factor-1, and 
signal transducers and activators of transcription (STATs) are activated by hypoxia. 
These factors activate TNF-α and interleukin-1β (IL-1β) within 2 h after the onset of 
ischemia. These cytokines activate glial cells, which then produce more cytokines, such 
as TNF-α, IL-1β and IFN-α. NF-κB was also shown to be involved in the production of 
iNOS and COX-2, which are important inflammatory mediators (Huang et al., 2006).  
Experimental attempts have therefore been made to diminish certain 
inflammatory elements in order to block the inflammatory response and explore the 
possible beneficial effects after focal ischemia. These strategies include anti- leukocyte 
infiltration, cytokine inhibition and anti-adhesion molecules (Danton and Dietrich, 2003; 
Zheng and Yenari, 2004).   Recent experiments showed that minocycline, an antibiotic, 
has the potential to inhibit inflammatory pathways and therefore exert neuroprotective 
effects in different CNS injuries (Danton and Dietrich, 2003).  
1.3.1.2 Minocycline in CNS Injury  
Minocycline is a second generation tetracycline derivative with antimicrobial 
activity. Recently it has been shown to have neuroprotective properties in animal models 
of acute CNS injury and neurological diseases, including brain ischemia (Yrjanheikki et 
al., 1998; Yrjanheikki et al., 1999), spinal cord injury (Lee et al., 2003; Wells et al., 
2003; Teng et al., 2004), traumatic injury (Sanchez Mejia et al., 2001), Huntington's 
disease (Chen et al., 2000), Parkinson’s disease (Du et al., 2001), and amyotrophic 
lateral sclerosis (ALS) (Zhu et al., 2002). Most of the evidence suggests that the 
neuroprotective effect of minocycline is associated with inhibition of iNOS as well as 
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IL-1β converting enzyme (ICE) expression, thereby preventing IL-1β formation 
following injury (Yrjanheikki et al., 1998; Chen et al., 2000; Du et al., 2001). 
Minocycline treatment also reduces expression of the matrix metalloproteinases (MMPs), 
which are involved in the breakdown of the blood-brain barrier and subsequent 
infiltration of inflammatory cells into the brain (Brundula et al., 2002; Koistinaho et al., 
2005). In addition to anti- inflammatory effects, minocycline can also modulate neuronal 
cell death by a direct interaction with the apoptotic machinery, possibly acting on 
caspase-dependent and –independent cell death mechanisms (Chen et al., 2000; Zhu et 
al., 2002; Wang et al., 2003).  
However, these encouraging results were not found in all studies. Lately, several 
studies found that minocycline lacks a beneficial effect or may even have detrimental 
effects. This was shown for Huntington’s disease (Diguet et al., 2003; Smith et al., 2003), 
Parkinson’s disease (Yang et al., 2003; Diguet et al., 2004b), hypoxic- ischemic brain 
injury (Tsuji et al., 2004) and spinal cord injury (Zang and Cheema, 2003). It has even 
been suggested that many negative effects were never reported and therefore the record 
of minocycline may be more questionable than the literature suggests (Diguet et al., 
2004a).  
With regards to stroke, minocycline showed beneficial effects in different animal 
models of global ischemia (Yrjanheikki et al., 1998; Yrjanheikki et al., 1999), transient 
and permanent focal cerebral ischemia (Yrjanheikki et al., 1999; Xu et al., 2004; 
Koistinaho et al., 2005) and  hypoxic-ischemic brain injury in neonatal rats 
(Yrjanheikki et al., 1999; Arvin et al., 2002; Fox et al., 2005). However, Tsuji et al. 
(2004) reported that minocycline could exacerbate hypoxic- ischemic brain injury in the 
developing mouse while providing mild protection in rat pups. Fox et al., (2005) found 
only a transient protection in rat pups. In a permanent MCAO in adult mice, minocycline 
treatment started before MCAO reduced the infarct size, whereas treatment initiated 
after MCAO was not protective (Koistinaho et al., 2005).  
Minocycline has been used in humans for decades as an antibiotic, particularly 
for treatment of acne and more recently has been used in the treatment of rheumatoid 
arthritis, proving to be safe. The half- life of minocycline in humans is between 16 and 
20 hours and it can be administered orally. It penetrates well into the brain and the 
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cerebrospinal fluid (CSF) and it is well tolerated by patients (Breedveld et al., 1990; 
Tilley et al., 1995). These characteristics make minocycline an appealing candidate in 
experimental studies and clinical trials for cerebral ischemia.  
1.3.2 Enhancing Adult Neurogenesis to Improve Recovery  
Neural cell replacement therapies are based on the premise that neurological 
function lost to injury or neurodegenerative disease can be improved by introducing new 
cells to replace the function of the lost neurons. These new neurons could improve the 
functional recovery of the host by integrating into the existing microcircuitry of the 
nervous system, therefore replacing lost neuronal circuits.  Alternatively, newly 
introduced cells could constitutively secrete growth factors to support the survival or 
regeneration of existing neurons (Ferretti, 2004; Lindvall et al., 2004; Lindvall and 
Kokaia, 2006).  
That continuous neurogenesis exists in the adult mammalian brain has been well 
accepted now. As well, there is recent documentation o f  increased endogenous 
neurogenesis in the adult mammalian brain after various brain injuries. This opens up 
the possibility to manipulate endogenous multipotent precursors in situ to replace lost or 
damaged neurons. Manipulation of endogenous precursors may have advantages over 
transplantation-based approaches as there is no need for external sources of cells, which 
are normally derived from either embryonic tissue or non-human species (Emsley et al., 
2005). In fact, neurogenesis has been documented in several focal ischemic models. 
However, the number of spontaneously regenerating neurons detected so far is low. 
Recent evidence of spontaneous neurogenesis, angiogenesis and synaptogenesis distant 
from the ischemic lesion points to a remodeling of the surviving tissue that may promote 
post-lesional brain plasticity (Roitberg, 2004). Understanding these processes may 
unveil hitherto unknown mechanisms that may become targets of future therapeutic 
interventions. However, the mechanisms underlying the beneficial effects of these 
therapies have not been fully investigated. Understanding endogenous neurogenesis after 
stroke may provide insights into enhancement of functional improvements. The 
following sections review research of normally occurring neurogenesis, findings from 
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experiments demonstrating endogenous neurogenesis after experimental focal ischemia, 
and finally, experiments regarding neocortical neurogenesis.  
1.3.2.1 Neurogenesis in the Adult Brain 
The consensus definition of neural stem cells (NSCs) remains controversial. In 
this thesis, the terms, “NSC”, “progenitors”, and “precursor cells” will be defined as 
recommended by recent reviews (Lledo et al., 2006; Sohur et al., 2006).  Neural stem 
cells are rigorously defined as cells from the nervous system that are capable of 
self-renewal, proliferation and multipotent differentiation into different neuroectodermal 
lineages of the CNS, including the multitude of different neuronal and glial subtypes. 
Multipotent neural progenitors of the adult brain are proliferative cells with limited 
self-renewal that can differentiate into at least two different cell lineages. CNS stem 
cells and all progenitors are generally referred to as precursors or precursor cells.  
Adult neurogenesis is referred to as a process of generating functional neurons in 
the adult brain. It is comprised of the entire series of events starting from the 
proliferation of precursor cells and ending with the functional integration of new mature 
neurons (Ming and Song, 2005; Lledo et al., 2006; Sohur et al., 2006). The adult brain 
has long been regarded as a non-regenerating organ. However, the recent development 
of new techniques for labeling dividing cells, the development of neuron-specific 
immunocytochemical markers, and confocal microscopy has resulted in the 
identification of continuous neurogenesis and possible multipotent neural progenitors in 
many parts of the adult mammalian brain. Contrary to previous beliefs about the adult 
brain, it is in fact capable of generating new neurons that can integrate into its complex 
circuitry.  
It is now well established and accepted that active neurogenesis in the normal 
adult rodent brain is not widespread, but is largely restricted to the two germinal areas, 
the hippocampal dentate gyrus (DG) and the subventricular zone (SVZ) of the lateral 
ventricles (Alvarez-Buylla and Lim, 2004; Lledo et al., 2006). The new neurons are 
found in the olfactory bulb (OB) and granule cell layer of the DG. They are derived from 
the neural stem cells residing in the SVZ and the subgranular zone (SGZ) of the DG, 
respectively. Neurons are generated continuously in the SVZ and migrate through the 
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rostral migratory stream [RMS] in the OB where they differentiate into interneurons. In 
the DG of the hippocampus, new granule neurons remain near their site of generation 
and become incorporated into the DG cell  layer (Taupin, 2006a). The present study 
focuses on the neurogenesis in the SVZ-RMS-OB axis.  
1.3.2.1.1 Neurogenesis in the SVZ-RMS-OB 
The SVZ (in some literature, it is also called subependymal layer/zone) is a 
remnant of the enlarged perinatal periventricular germinative area. During development, 
this germinative area narrows to the most rostral part of the lateral ventricle and forms 
the SVZ, which persists through adulthood (Tramontin et al., 2003). In the perinatal 
period the SVZ can be subdivided into several anatomical regions. The anterior SVZ 
(SVZa), which is located rostral to the frontal tip of the lateral ventricle, has been 
characterized as the major source of the cells in the RMS. The dorsolateral SVZ (SVZdl) 
is a large pocket of cells situated at the dorsolateral aspect of the lateral ventricle at the 
level of the anterior commissure that is regarded as a major source of forebrain neuroglia 
(Brazel et al., 2003). Only neurogenesis in the SVZa persists to adulthood. When 
retrovirus, bromodeoxyuridine (BrdU) or vital dye is microinjected into the anterior 
portion of the SVZ of adult rodents, labeled cells migrate through the RMS and are 
eventually found in the OB. Once reaching the OB, these labeled cells migrate radially 
and differentiate into olfactory granule neurons and to a much lesser extent, 
peri-glomerular interneurons (Luskin, 1993; Lois and Alvarez-Buylla, 1994). However, 
in vitro, cells can be isolated from the adult SVZ and expanded in culture to form 
neurospheres, which generate both neurons and glia (Reynolds and Weiss, 1992; Lois 
and Alvarez-Buylla, 1993). As such, the SVZ represents an important reservoir for 
precursors in the adult brain and could potentially provide a useful resource for 
neurogenerative therapy.  
The continuous neurogenesis in the adult SVZ suggests that the neural stem 
cells/ multipotent progenitors reside in this germinal area. To date, at least four different 
cell types have been identified in this SVZ-ependymal region: types A, B and C and 
ependymal cells, which line the lateral ventricle and separate the SVZ from the ventricle 
cavity (Doetsch et al., 1997). Type A cells are migrating neuroblasts (young migrating 
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neurons) and they organize as chains in the SVZ and RMS. Type C cells are highly 
proliferative precursors (fast dividing transient amplifying cells) scattered in small 
clusters along the chains of migrating neuroblasts (A cells). Type B cells are GFAP and 
nestin expressing astrocytes. They were named SVZ astrocytes because they express 
astrocytic intermediate filaments, such as GFAP, vimentin and nestin. Despite the  
nomenclature of these cells, it is important to distinguish between true astrocytes and 
GFAP-expressing SVZ cells. It has been reported that the GFAP-expressing astrocytes 
in the SVZ have a bipolar or unipolar morphology that has significantly fewer processes 
than true astrocytes. Type B cells form a tube- like structure ensheathing the chains of 
migrating neuroblasts and they also interact closely with the ependymal cells separating 
lateral ventricle from the SVZ. Similar to what has been observed in embryonic neural 
progenitors, type B cells also contain single cilia that extend into the ventricle lumen 
through the ependymal barrier. Type C cells are the most frequently dividing cells in the 
SVZ, but both B and A cells also undergo cell division. One hour after a single 
[3H]-thymidine injection, 52% of the labeled cells in the SVZ were type C cells, 15% are 
type A, and 12% were type B. The remaining 21% were not identified. Based on the 
proportions of the different cell types in the SVZ, it seems that type C cells are 10 times 
more likely to divide than type A or B cells (Doetsch et al., 1999).   
The nature of the stem cells in the SVZ has been the subject of controversy for a 
long time. Two potential sources have been suggested: ependymal cells or 
GFAP-expressing astrocytes (Chiasson et al., 1999; Doetsch et al., 1999; Johansson et 
al., 1999). Eventually, this later theory has been confirmed by the work of 
Alvarez-Buylla and his colleagues (Doetsch et al., 1999). In this paper, they showed that 
after elimination of immature precursors (type C cells) and neuroblasts by antimitotic 
treatment, only the SVZ astrocytes were left. This cell type divided to generate immature 
precursors and neuroblasts. In addition, using a transgenic mouse expressing the receptor 
for an avian retrovirus under the control of the GFAP promoter, after specifically 
labeling astrocytes of the SVZ by targeting an avian retrovirus carrying the reporter gene 
to this region, they found labeled neurons in the OB. They showed that SVZ astrocytes 
are able to give rise to cells that grow into multipotent neurospheres in vitro (Doetsch et 
al., 1999). Since then, more studies have confirmed that the SVZ GFAP-expressing 
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astrocytes are the primary progenitors in vivo (Imura et al., 2003; Garcia et al., 2004). 
By employing a transgenic GFAP-TK mouse, which expresses virus thymidine kinase 
(TK) under mouse GFAP promoter, the authors showed that the new neurons in the OB 
are depleted after elimination of the GFAP-expressing cells by the antiviral agent 
ganciclovir. In addition, they used Cre/lox technology and generated GFAP-Cre reporter 
mice in which all GFAP-expressing cells and their progeny expressed the reporter even 
if the expression of GFAP and Cre was downregulated (Garcia et al., 2004). Results 
from these transgenic mice show that all new neurons generated in the adult mouse 
forebrain are derived from GFAP-expressing cells. Overall, both in vivo and in vitro 
evidence shows that GFAP-expressing type B cells function as neural stem cells / 
multipotent precursor cells. In the adult SVZ, the slowly proliferating GFAP-expressing 
astrocyte- like cells (type B cells) differentiate to become rapidly dividing immature 
progenitors (type C cells) and generate migrating neuroblasts (type A cells), which 
migrate in chains through the RMS to the OB.  
Once neuroblasts are born in the SVZ, they migrate along the RMS to their final 
destination in the OB. This is a 5-8 millimeter distance in the mouse. For a cell that is 
only 10-30 µm long, this translates into a long distance to migrate within only 2 to 9 
days (Doetsch and Alvarez-Buylla, 1996). How do these cells move such a long distance 
and transverse the dense parenchyma of the adult brain? Neuroblasts in the SVZ of adult 
rodents, unlike the neuroblasts in the developing cerebellum, cortex, or adult avian 
telencephalon, use a novel form of neuronal migration, called tangential chain migration. 
As mentioned above, in adult rodent SVZ and RMS, migrating neuroblasts (A cells) 
form a long chain and move along each other and are surrounded by a tube- like structure, 
which is formed by processes from astrocytes (type B) (Lois and Alvarez-Buylla, 1994; 
Jankovski and Sotelo, 1996). Migrating neuroblasts have elongated morphologies with a 
leading process tipped by a growth cone  (Lois and Alvarez-Buylla, 1994). Chain 
migration has been demonstrated in vitro using explant cultures of the SVZ.  In these 
cultures, neuroblasts escape the explant, assemble as chains and move in incremental 
steps at an average speed of 120 µ m/h by sliding along each other (Wichterle et al., 
1997).  Constantly using their leading processes to explore the surrounding 
environment, these cells appear to respond to unidentified signals that trigger the cell 
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body to move. Chain migration in vitro occurs in conditions completely devoid of glial 
cells.  
Neuroblasts are produced in excess by the SVZ and they migrate to the OB, 
where they arrive 3 to 5 days later. Over the course of the next 10-25 days, they migrate 
into their proper positions in the OB, mature and become interneurons. More than 
30,000 neuroblasts exit the rodent SVZ for the RMS each day (Alvarez-Buylla et al., 
2001). Many die, probably during migration, and 50% or more are lost 15 to 45 days 
after they arrive in the OB (Petreanu and Alvarez-Buylla, 2002). Once the cells reach the 
core of the OB, they are separated from the chains, migrate radially to more superficial 
layers ( granule cell and external plexiform layers), where they differentiate into the 
olfactory inhibitory interneurons of two main types, granule neuron and periglomerular 
neurons. Both type of interneurons lack an axon and instead have reciprocal 
dendro-dendritic synapses with mitral and tufted cells, modulating the processing of 
sensory information (Carleton et al., 2003; Lledo et al., 2006).  
 
 
 
1.3.2.1.2 Neurogenesis in the DG of the Hippocampus 
The neural progenitors in the adult hippocampal dentate gyrus are located in the 
SGZ of the hippocampus, which is at the border of the hilus and dentate granule cell 
layer. In the SGZ of the hippocampus, it was also shown that GFAP-expressing SGZ 
astrocytes are the primary neural precursors (Picard-Riera et al., 2004). These astrocytes 
with their cell bodies in the SGZ have radial processes going through the granule cell 
layer and short tangential processes extending along the border of the granule cell layer 
and hilus. These GFAP- and nestin-expressing astrocytes divide via asymmetric division 
and give rise to amplifying progenitors that proliferate in clusters and generate DCX+ 
and PSA-NCAM+ neuroblasts. O ver 9,000 neuroblasts are produced per day in young 
adult rats (Cameron and McKay, 2001). These neuroblasts disperse and migrate a very 
short distance into the granular cell layer of the DG, where they differentiate into 
granule neurons. Later, the newly generated DGCs send axonal projections to the CA3 
area. During this early postmitotic stage, the new neurons are apparently recruited in a 
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functional role, or die (Kempermann et al., 2004). The adult-born DGCs are 
morphologically and electrophysiologically indistinguishable from the existing cells and 
appear to functionally integrate into the circuitry of the dentate gyrus (Emsley et al., 
2005; Lichtenwalner and Parent, 2006). Although the precise functional role of 
hippocampal neurogenesis in the adult mammalian brain is unknown, it is suggested that 
the new neurons might play a role in hippocampal-dependent learning and memory 
(Lledo et al., 2006).  
1.3.2.1.3 Neurogenic Potential of the Cortex and other Regions of the Mature Brain  
Although ongoing neurogenesis in the adult DG of the hippocampus and OB is 
widely accepted, whether neurogenesis exists in other brain regions in adulthood 
remains a topic of debate. Reports of persistent neurogenesis in the cortex can be traced 
as far back as several decades (Altman, 1963; Kaplan, 1981). Although neural 
multipotent progenitors have been isolated from the cortex (Palmer et al., 1999), it is still 
very controversial whether neurogenesis persists in vivo in the neocortex of the adult 
mammalian brain (Lichtenwalner and Parent, 2006).  A  research group claimed the 
existence of an extremely low level of neurogenesis in the neocortex of the adult primate 
(Gould et al., 1999). Later on, this group modified their interpretation by stating that the 
existence of these neurons was only transient (Gould et al., 2001). However, other 
groups disputed these results primarily on methodological grounds (Kornack and Rakic, 
2001; Koketsu et al., 2003), and a recent study suggested there is no neurogenesis in the 
neocortex of adult human brain (Bhardwaj et al., 2006).  
In addition, there are some reports of the production of new neurons in the adult 
amygdala  (Bernier et al., 2002), substantia nigra (Zhao et al., 2003), dorsal vagal 
complex of the adult brainstem (Bauer et al., 2005), primary visual cortex (Kaplan, 
1981), spinal cord (Yamamoto et al., 2001) and striatum (Dayer et al., 2005). These 
reports suggest that the existence of low-level neurogenesis in the adult mammalian 
brain might be a widespread phenomenon. However, some of these results have been 
disputed (Cooper and Isacson, 2004; Frielingsdorf et al., 2004).  
In vitro results suggest that neural progenitor cells may also reside in other 
regions of the adult brain (Gottlieb, 2002). Multipotent neural progenitors have now 
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been isolated from various non-neurogenic regions of the adult mammalian CNS, such 
as spinal cord (Weiss et al., 1996; Shihabuddin et al., 1997), striatum (Reynolds and 
Weiss, 1992; Palmer et al., 1995), optic nerve (Palmer et al., 1999), retina (Tropepe et al., 
2000), corpus callosum (Kondo and Raff, 2000), septum (Palmer et al., 1995) and 
hypothalamus (Lie et al., 2002). When cultured in the appropriate media, these cells 
have been shown to have multilineage potency and self- renewing ability. When exposed 
to high concentrations of mitogens, such as FGF-2 and / or EGF in serum-free medium, 
isolated precursor cells proliferate. After withdrawing the mitogen or exposing the cells 
to instructive factors, these cells promptly differentiate into three main cell types of the 
CNS; neurons, astrocytes and oligodendrocytes in vitro (Gage, 2000). It has to be 
pointed out that although these studies contribute useful information, one should not 
forget that cell culture systems are highly artificial in many respects and do not 
reproduce in situ conditions very well (Sohur et al., 2006). In vivo, precursor cells are 
accompanied by other cells and their microenvironment is inseparable from their 
inherent properties.  
These in vivo and in vitro studies suggest that multipotent neural progenitors may 
be present throughout the adult CNS and their neuronal differentiation could be 
influenced by their local environment. The nature of the signals and factors that promote 
neuronal differentiation of these precursors is still unknown.  
1.3.2.1.4 Neurogenesis in Adult Human and Nonhuman Primates  
Dentate granule cells (DGCs) continue to be generated throughout life in adult 
human and nonhuman primates. Several groups have shown neuronal birth in the dentate 
gyrus of monkeys by showing that cells incorporating the S-phase markers tritiated 
thymidine or BrdU differentiate into neurons several weeks later (Kornack and Rakic, 
1999). In the human dentate gyrus, new DGCs continue to be generated even as late as 
the seventh or eighth decade of life (Eriksson et al., 1998).  
Neuronal production also appears to continue in the adult SVZ-olfactory bulb 
pathway of primates (Kornack and Rakic, 2001). The adult primate SVZ underlies the 
ventral and lateral walls of the lateral ventricle. SVZ neuroblasts migrate in the RMS as 
a thick chain surrounded by an astrocytic net (Pencea et al., 2001a). Neurospheres can be 
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generated from the adult human subependymal zone of the lateral ventricle. Similarly to 
rodents, these adult human neurospheres give rise to functional neurons and glia 
(Westerlund et al., 2003). Chain migration of neuroblasts away from the lateral 
ventricles is not apparent in the human adult brain (Sanai et al., 2004). It has also been 
suggested that similar migrations may occur in the infant human brain (Weickert et al., 
2000). Evidence suggests, however, that new neurons are added to the adult human 
olfactory bulb (Bedard and Parent, 2004) and their source therefore is uncertain. By 
utilizing the 14C integration and BrdU techniques, a recent study suggested no 
neocortical neurogenesis exists in the adult human brain. The neurons in the human 
neocortex are generated perinatally, but not generated in adulthood at detectable levels 
(Bhardwaj et al., 2006). 
1.3.2.2 Post-stroke Neurogenesis  
 The presence of ongoing neurogenesis and multipotent neural progenitors in the 
mature forebrain raises the question: Could these precursor cells serve as an endogenous 
source for replacement after neural loss associated with brain injury? Several 
investigations have found increased cell proliferation and neurogenesis in the adult 
rodent forebrain SVZ after various forms of injury, such as cortical aspiration (Szele and 
Chesselet, 1996), inflammatory demyelination (Calza et al., 1998) and focal ischemia 
(Jin et al., 2001; Zhang et al., 2001). The increased neurogenesis in the SGZ has also 
been demonstrated in different experimental stroke models, such as transient global 
ischemia in the gerbil (Liu et al., 1998), mouse (Takagi et al., 1999), rat (Yagita et al., 
2001) and in the rat MCAO model of focal ischemia (Arvidsson et al., 2001; Dempsey et 
al., 2003). With regards to stroke, it has been found that cerebral ischemia enhances not 
only neurogenesis in the SVZ and SGZ, the neurogenic areas of adult brain, but also the 
non-neurogenic areas such as striatum, cortex and hippocampus. Newborn neurons have 
also been observed in the ipsilateral striatum (Arvidsson et al., 2002), neocortex (Jiang 
et al., 2001), in animal models of MCAO and in the degenerated hippocampal CA1 
(Nakatomi et al., 2002). Some studies suggest that a small portion of these newly 
generated neurons is functionally integrated in the circuits (Chen et al., 2004). These 
data highlight the potential of endogenous precursors for cellular therapy. Understanding 
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of the contribution and mechanisms of stroke-induced neurogenesis to the 
pathophysiology of cerebral strokes will allow significant advances in the understanding 
of cerebral strokes, and their therapy.  
To study neurogenesis, BrdU is often used as a marker for dividing cells. BrdU, a 
thymidine analog that is incorporated into the DNA of dividing cells during S-phase, 
labels dividing cells and passes the label on to the progeny. BrdU can be detected by 
immunocytochemistry and can be combined with double or triple labeling with the 
neuron-specific markers. It therefore allows the detection of newly generated neurons. 
The first evidence of regenerative neurogenesis was reported in the neocortex by Magavi 
et al., ( 2000). They used a biophysical approach to induce synchronous apoptotic 
degeneration of corticothalamic neurons in layer VI of the anterior cortex of adult mice. 
Importantly, other cells in the regions surrounding those neurons targeted for death were 
not injured. Using BrdU as well as phenotype specific markers of progressive neuronal 
differentiation, they found that newborn cells (BrdU+) progressively developed 
expression of the mature neuronal marker NeuN, and survived to at least 28 weeks. Two 
weeks after injury, they also found subsets of BrdU+ cells with morphology of 
migratory neuroblasts expressing doublecortin (DCX), a protein found exclusively in 
migrating neurons, and Hu, an early neuronal marker. A subset of these newly generated 
mature BrdU+ and NeuN+ positive neurons were also able to form appropriate 
long-distance thalamic projections as shown with the retrograde label FluoroGold. 
Where do these new-born neurons originate? Although there are no detailed studies of 
the exact locations of the endogenous precursors, in this paper (Magavi et al., 2000) the 
authors suggested two potentially co-existing sources: the main source appeared to 
originate in the SVZ, whereas a small source appeared to be precursors resident within 
the cortex itself. More recently, the same group modified the location of targeted cell 
death to the corticospinal motor neurons in Layer V of the motor cortex in adult mice 
(Chen et al., 2004). They found that BrdU+/DCX+ cells, adopted the morphology 
typical of migrating neurons in the developing brain. These cells are located only in or 
under the corpus callosum and cortical layers VI and V undergoing targeted CSMN 
degeneration. Later, BrdU+ newborn cells expressed the early neuronal marker Hu. 
NeuN, a mature neuronal marker, was expressed within 2 to 4 weeks in the same region 
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where BrdU+/DCX+ cells were found. These newborn neurons survived for at least 56 
weeks and a portion of the new neurons extended axons to the spinal cord and formed 
long-distance corticospinal connections (Chen et al., 2004). When immature neurons or 
neural precursors were transplanted into this degenerating cortex, they could migrate 
selectively to the appropriate cortical layer and differentiate into projection neurons, 
receive afferent synapses, express appropriate neurotransmitters and receptors, and form 
appropriate long-distance connections to the original contralateral targets of the 
degenerating neurons (Snyder et al., 1997; Sheen et al., 1999). 
Taken together, these results demonstrate that endogenous neural precursors 
can be induced in situ to differentiate into cortical neurons, survive for many months and 
form appropriate long-distance connections in the adult mammalian brain and the 
microenvironment plays a very important role in influencing the potential of neural 
precursors (Sohur et al., 2006). However, it seems the production and integration of 
these newborn neurons are relatively low and the functional consequences of this 
neurogensis after this specific injury remain to be determined. Moreover, it is possible 
that the adult cortex undergoes targeted apoptotic degeneration of projection neurons 
and forms an instructive environment for guiding the differentiation of neural 
precursors. This lesion might have only destroyed the targeted neurons without inducing 
inflammatory responses, gliosis, or activated cytokine-release stage microglia (Sheen 
and Macklis, 1994; Wang et al., 1998b). Ischemic injury is a more complicated process 
than the targeted apoptotic model system.  
Accumulating evidence suggests that ischemic injury can induce neurogenesis in 
the hippocampus and striatum, and possibly neocortex as well. This section will focus on 
the recent studies addressing the response to ischemia and whether neuronal replacement 
from endogenous precursors occurs in regions of the adult brain that do not normally 
undergo neurogenesis. This includes the neocortex, striatum and hippocampal CA1 area 
following focal ischemia. 
1.3.2.2.1 Post-stroke Neurogenesis in the Hippocampal Formation 
Increased neurogenesis in the SGZ has been demonstrated in different 
experimental stroke models, such as the transient global ischemic model of the gerbil 
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(Liu et al., 1998), mouse (Takagi et al., 1999) and rat (Yagita et al., 2001), and the rat 
MCAO model of focal ischemia (Arvidsson et al., 2001; Dempsey et al., 2003).  These 
studies provide no evidence of neuronal replacement of dead neurons in the lesioned 
region, such as CA1. However, recent studies showed that new neurons are found at the 
sites of the lesioned area after transient global ischemia, such as the CA1 area of the 
hippocampus. Nakatomi et al. (2002) reported a modest regeneration of CA1 pyramidal 
neurons (BrdU+ cells co-expressing neuronal markers such as Hu, NeuN, and ßIII 
-tubulin) within 4 weeks after a transient global ischemic model, induced by transient 
four-vessel occlusion and systemic hypotension in adult rats. Intraventricular infusion of 
epidermal growth factor and FGF-2 during the first week after global ischemia leads to a 
remarkable increase of regeneration in damaged CA1 neurons. These neurons 
differentiate into electrophysiologically functional neurons with the morphological 
characteristics of pyramidal cells and integrate into existing brain circuitry, contributing 
to the amelioration of the special learning deficits caused by global ischemia. Cell 
tracing studies using retrovirus and DiI labeling revealed that the newly generated 
neurons in the CA1 area might arise from the progenitors that reside in both the posterior 
periventricular region near the hippocampus a n d  hippocampal parenchyma. 
Neurogenesis in the hippocampal pyramidal cells has also been reported in an adult 
gerbil model of transient global ischemia (Schmidt and Reymann, 2002). However, 
other studies in the gerbil model have not found CA1 neuron regeneration (Liu et al., 
1998).    
1.3.2.2.2 Post-stroke Neurogenesis in the Striatum 
Neurogenesis in the ipsilateral striatum has been reported in animal models using 
MCAO in both rats and mice (Arvidsson et al., 2002; Parent et al., 2002; Jin et al., 2003; 
Zhang et al., 2004; Nygren et al., 2006b; Yamashita et al., 2006). At around 2 weeks 
after injury, migrating neuroblasts / immature neurons were observed in the striatum as 
indicated by the expression of neuronal cell lineage markers such as DCX and / or 
βIII-tubulin. Some of these cells also co- labeled with BrdU. This indicates that they are 
newly generated (Arvidsson et al., 2002; Parent et al., 2002). Almost all of the DCX 
expressing cells after stroke in the striatum also expressed βIII-tubulin (Yamashita et al., 
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2006), the marker Meis2, and Pbx proteins, which are normally expressed within 
developing striatal medium-sized spiny neurons (Toresson et al., 2000; Arvidsson et al., 
2002). A small percentage of DCX+ cells also expressed the mature neuronal marker 
NeuN (Arvidsson et al., 2002; Jin et al., 2003). At weeks 5-6 after a stroke, the new 
neurons had the typical morphology of mature neurons and expressed NeuN as well as 
mature striatal medium-sized spiny neuron markers, such as DARPP-32 and calbindin. 
They were found in the damaged area and in the unaffected medial striatum (Arvidsson 
et al., 2002; Parent et al., 2002; Yamashita et al., 2006). Months later, although some of 
the newly generated neurons die through caspase mediated apoptosis, a subset of these 
newborn neurons were found to form synapses with neighboring striatal cells in the 
damaged striatum (Thored et al., 2006; Yamashita et al., 2006). Thus, the new neurons 
differentiate into the phenotype of most of the neurons that were destroyed by the 
ischemic lesion. These data strongly suggest that the endogenous precursor cells can be 
induced to differentiate into functional mature neurons and can replace some of the 
damaged neurons.  
There are two possible sources for the newly generated neurons in the ischemic 
striatum after MCAO. The first possible source is the SVZ, as the neuroblasts born in 
this location might migrate toward the ischemic striatum. DCX+ cells forming chain- like 
structures extending from the SVZ toward the ischemic striatum were observed (Jin et 
al., 2003; Zhang et al., 2004). This migratory appearance is similar to the normal RMS 
chain migration of SVZ neuroblasts to the OB. These chains were closely associated 
with thin astrocytic processes and blood vessels (Yamashita et al., 2006). The second 
possible source is the striatal parenchyma, because it also contains latent progenitors that 
can be activated and become neurogenic when stimulated by neurotrophic factors 
(Palmer et al., 1995; Pencea et al., 2001b). Using the Cre- loxP recombination system, 
which enables region-specific cell labeling and long-term tracing, Yamashita et al. (2006) 
confirmed that the SVZ cells were the primary source of this newly generated striatal 
neurons after MCAO. Furthermore, using the cell-type-specific viral infection method, 
which only labels SVZ GFAP-expressing cells, they confirmed t h a t  SVZ 
GFAP-expressing cells are the primary source of striatal neurogenesis after MCAO. 
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1.3.2.2.3 Post-stroke Neurogenesis in the Cortex 
As mentioned above, cortical neurogenesis can be induced in the injured adult 
neocortex by targeting apoptotic degeneration (Magavi et al., 2000; Chen et al., 2004). 
However, this lesion is very different from ischemic injury because it only destroyed the 
targeted neurons without induction of gliosis. Whether neurogenesis can still occur after 
a stroke that has caused extensive cortical damage is not clear.  Although the MCAO 
induced excessive injury in both the striatum and cerebral cortex, the reports of whether 
neurogenesis in the peri- infarct cortex occurs, are not consistent. It has been shown in a 
cortical reversible photothrombotic stroke model that a small subset of dividing and 
BrdU+ cells co-expressed the neuronal markers Map-2 and NeuN in the peri- infarct area, 
and was distributed randomly in the cortical layers II-VI (Gu et al., 2000). Later on, the 
same group reported the presence of double- labeled cells by BrdU and other 
neuron-specific markers, Map-2, β-tubulin III, and NeuN in the peri- infarct of both 
damaged cerebral cortex and striatum after tMCAO (Jiang et al., 2001). A similar 
presence of immature neurons in the cortex after MCAO was reported (Jin et al., 2003). 
This cell- tracking study using the lipophilic carbocyanine tracer DiI suggests that the 
SVZ cells migrate via the lateral cortical stream into the penumbra of the ischemic 
cortex and striatum. However, four other studies (Arvidsson et al., 2002; Parent et al., 
2002; Zhang et al., 2004; Yamashita et al., 2006), did not detect any BrdU+ cells 
co-labeled with neuronal markers in the injured cortex following MCAO despite their 
appearance in the striatum. In an irreversible ischemic cortical injury, induced by 
thermocoagulation of pial blood vessels, cells expressing DCX, a protein exclusively 
expressed by migrating neuroblasts and immature neurons, were present in the striatum 
and corpus callosum but not in the peri- infarct cortex 5 days after initiation of the injury. 
Furthermore, one month later, no BrdU+ cells expressing NeuN were detected in any 
region. These results suggest that new neurons do not form or survive in the neocortex 
under this experimental condition. A recent study has reported a substantial production 
of new neurons in response to a cortical focal ischemic injury. One week after a cortical 
ischemic injury, more than 10,000 neuroblasts (DCX+) cells per animal were present in 
the peri- infarct neocortex. Three months later, it seemed that around 10% of these 
neuroblasts survived and differentiated into mature neurons in the peri- infarct area as 
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suggested by the number of BrdU+/NeuN+ cells (Ohab et al., 2006; Tsai et al., 2006). 
Using genetic and viral labeling methods, the authors showed that cortical ischemic 
injury induced the production of new neurons from the SVZ via GFAP-expressing cells 
and migration of these newborn neurons into a unique neurovascular niche in 
peri- infarct cortex (Ohab et al., 2006; Tsai et al., 2006).    
Taken together, these results suggest t ha t  endogenous neural precursors are 
potentially capable of being recruited and induced to differentiate into cortical neurons 
in the ischemically damaged cortex, but only if the instructions or survival cues 
necessary for neurogenesis are present and are not suppressed. Elucidation of the 
appropriate signals necessary for neuronal differentiation or survival could enable CNS 
repair after stroke.  
1.4 Animal Models of Focal Ischemia 
To understand the pathogenesis of stroke and to evaluate preventive or 
therapeutic strategies, experimental animal models of focal and global ischemia have 
been developed in many different species, both small and large (e.g., mice, rats, gerbil, 
cats and primates). Rodent models are most commonly used due to their low cost, easy 
maintenance and reproduction, and close resemblance to higher species (Traystman, 
2003). Although many animal stroke models have been developed, however, there is no 
one perfect model which alone is able to mimic human stroke conditions. This is 
because of the diversity of human stroke in terms of the cause, manifestation and 
anatomic sites of the ischemic lesion (Traystman, 2003).  
Animal models of cerebral ischemia are divided into global and focal. 
Essentially, cerebral ischemia in both focal and global models consists of the reduction 
of oxygen and glucose supply to brain tissue. Global ischemia occurs when cerebral 
blood flow is reduced throughout most or all of the brain, whereas focal ischemia is 
represented by a reduction in blood flow to a very distinct, specific brain region  
(Ginsberg and Busto, 1989). An important variable affecting stroke outcome is the 
presence or absence of reperfusion following an ischemic event. Reperfusion occurs in a 
substantial proportion of human stroke patients, due to spontaneous early clot lysis, 
collateralization or clinical intervention, such as tPA treatment (Richard Green et al., 
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2003).  Accordingly, there are two basic classes of the experimental focal ischemic 
model: reversible (transient) and permanent. In permanent focal ischemia, the arterial 
blockage is maintained permanently throughout the experiment, whereas in transient 
focal models, vessels are blocked temporarily, usually from 1 to 3 h, to mimic the 
prolonged reperfusion in clinical settings (Aronowski and Labiche, 2003).  It appears 
that early reperfusion after a stroke is beneficial and capable of reversing the majority of 
ischemic dysfunctions, whereas, in some instances, late reperfusion may contrarily 
trigger deleterious processes and lead to more ischemic damage (Aronowski and 
Labiche, 2003; Schaller and Graf, 2004). 
The most commonly used focal ischemia models often involve permanent or 
temporary occlusion of the middle cerebral artery and are widely used to mimic the 
human stroke condition of large artery occlusion (Ginsberg and Busto, 1989). MCA 
supplies the basal ganglia, internal capsule and the lateral surface of the cerebral cortex 
(Aronowski and Labiche, 2003) and 25% of first-time human ischemic strokes involve 
infarcts in the MCA territory (McAuley, 1995; Richard Green et al., 2003). Therefore, 
the MCAO model has great relevance for human ischemic stroke.  Different occlusion 
sites and techniques are therefore used and there are many versions of MCAO models, 
such as: proximal MCAO model (Tamura model); intravascular thread model (Koizumi 
model); distal MCAO with bilateral common carotid artery occlusion model (Chen 
model); and photothrombosis model (Watson model). To obtain reproducibility of flow 
reduction and lesion size in MCAO, two principal occlusion sites are used: proximal and 
distal. Proximal MCAO leads to an extensive infarction of the basal ganglia and the 
neocortex, whereas a more distal occlusion leads to a smaller infarct, including 
neocortical infarction only (McAuley, 1995). Permanent occlusion can be obtained by 
microsurgical coagulation, by introducing an embolism o r  by insertion of an 
intraluminal suture (Windle et al., 2006). If the thread is withdrawn, conditions of 
reversible reperfusion are mimicked. Transient MCAO can also be induced by injection 
of endothelin-1 (ET-1) (Robinson et al., 1990). MCAO models produce a substantial 
amount of injury in many different brain regions but do not normally affect the motor 
cortex. These models mimic large artery occlusion in humans (Carmichael, 2005).  
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Human strokes are mostly small in size (Carmichael, 2005) and can occur as 
end-arteriolar or small vessel occlusion (McAuley, 1995). In rodents, small-size 
infarction of the motorsensory cortex has been induced by different techniques, such as 
photothrombosis, ET-1 injection, or devascularization.  E ach model h a s  its own 
advantages and disadvantages. Photothrombosis induces small vessel occlusion and is 
achieved by systematic injection of Rose-Bengal or other photosensitive dyes. Focal 
illumination of the targeted brain area through the intact skull leads to platelet 
aggregation with formation of clots and thrombotic occlusion of small intracerebral 
vessels (Watson et al., 1985; Dietrich et al., 1987a). The advantages of this model are 
the small size of infarcts, the ability to place the infarct within distinct functional 
subdivisions of the cortex and the minimal surgical manipulation of the animal. 
However, it was shown that Rose Bengal interferes with glutamate transport, which 
somewhat invalidates this model (Ogita et al., 2001). Another technique to induce 
ischemic cortical infarct is the use of ET-1, which is a potent and long-acting venous and 
arterial vasoconstrictor (Macrae et al., 1993; Reid et al., 1995). Intracortical injection or 
topical application of ET-1 produces a local dose-dependent well-defined ischemic 
lesion (Hughes et al., 2003). However a variation of this model used by other groups 
produced injuries that varied in size (Adkins-Muir and Jones, 2003) or no 
dose-dependency at all (Windle et al., 2006). The optimal placement of the ET-1 dosage 
for a reproducible cortical infarct and for sensorimotor deficits has not yet been 
established. Devascularization of all the cortical pial vessels of an exposed cortical 
surface is also used to induce cortical injury (Conner et al., 1998; Kolb et al., 2006). All 
three models have the advantage of providing a precise injury location whereas the 
photothrombosis model and intracortical injection of ET-1 model require less surgical 
intervention of the animals. The devascularization model was criticized because 
mechanical removal of the pial surface vessel might induce mechanical injury.  
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2. RATIONALE & OBJECTIVES  
Animal models of focal ischemia are useful tools in understanding the pathology 
and treatment of human stroke. Recent developments in the genesis and pathophysiology 
of experimental stroke in animal models suggest that protection and repair processes 
after such an injury should be the major focuses of therapeutic approaches in future 
stroke (Hossmann, 2006). 
Ischemic stroke causes not only localized ischemic cell death in the brain but 
also triggers a strong inflammatory response, gliosis and a regenerative response in the 
tissue surrounding the ischemic area core. Post- ischemic inflammation plays an 
important role in secondary brain damage following stroke. Therefore, 
anti- inflammatory intervention has been considered important for therapeutic 
approaches based on neuroprotection. Minocycline, a second generation of tetracycline, 
has been shown to have neuroprotective effects in different animal models of acute and 
chronic neurodegenerative disease including stroke, possibly through its 
anti- inflammatory and anti-apoptotic effects (Yong et al., 2004). Stroke also triggers a 
regenerative response in the tissue surrounding the area of cell death. Stroke enhances 
neurogenesis in both neurogenic and non-neurogenic areas. In the rodent brain, 
post-stroke neurogenesis has been observed in the peri- infarct of striatum (Arvidsson et 
al., 2002) and/or the cerebral cortex (Ohab et al., 2006) in the MCAO model. SVZ, the 
biggest pool of neural stem cell/neural progenitors of adult brain, seems to be the 
principle source of this post-stroke neurogenesis after MCAO (Jin et al., 2003; 
Yamashita et al., 2006). 
In the past, most focal cerebral ischemic investigations have focused on the 
occlusion of very large blood vessels, such as in the MCAO model. However, small 
vessel stroke does regularly occur in human stroke and accounts for approximately one 
third of human strokes (McAuley, 1995; Greenberg, 2006). If only large size animal 
stroke models are used, this will lead to a potential bias against the clinical situation   
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(Carmichael, 2005). In this thesis, a rat stroke model was selected, which mimics the 
human small vessel stroke, and two potential mechanisms, depressing inflammation with 
minocycline and neurogenesis of endogenous progenitor cells, have been applied to this 
model.  
 I hypothesize that targeting the non-neuronal cells in a small-vessel stroke will 
improve the outcome. The detailed objectives are as follows: 
  
1. To use a modified cortical devascularizing model, pial vessel II occlusion model, 
and to evaluate its usefulness in novel strategies of neuroprotection.  
 
2. To compare the effectiveness of this irreversible stroke model with another model of 
focal stroke, but with reversible blood flow obstruction.  
 
3. To assess the potential benefits of minocycline treatment after such an experimental 
stroke and analyze its mode of action.   
 
4. To compare the effectiveness with which various tracing techniques label cells 
migrating out of the SVZ.  
 
5. To examine whether new migrating neuroblasts appear near the lesion. 
 
6. To identify the source of such migrating neuroblasts. 
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3. MATERIALS AND METHODS  
3.1 Animals 
Adult male Wistar rats (250g-350g) were used for the Pial vessel II disruption 
model (PVD II) and Long Evans rats (250g~350g) were used for the topical application 
of ET-1 model. All the rats were supplied by Charles River Inc. (St. Constant, QC, 
Canada). After arrival, all animals were housed in cages of two rats each, and were kept 
for at least 1 week before being used in any procedure. They were exposed to a 12 hour 
light and dark cycle. Animals had free access to standard food and water. The guidelines 
of the Canadian Council of Animal Care in conjunction with the University Committee 
on Animal Care and Supply were followed for all experimental procedures ( Protocol 
identification number 20020024). 
3.2 Surgical Procedures 
The equipment and surgical area were sterilized in accordance with institutional 
guidelines. The head of the anesthetized animal was shaved around the surgical area 
before being mounted in the stereotaxic frame. The scalp was sterilized with povidone 
iodine twice followed by alcohol.  
Two animal models,  ( t opical endothelin-1  application a n d  modified cortical 
devascularizing model) were used.  
3.2.1 Topical Endothelin-1 Application 
Long Evans male rats were anesthetized by inhalation of halothane in 100% 
oxygen using a Boyle anesthetic machine. The induction of anesthesia was obtained by 
4~5% halothane inhalation for 5 to 10 minutes in a sealed box. After the loss of response 
to the pinch test of the hind paws and tail (pedal reflex), the rats were shaved and placed 
into a stereotaxic apparatus. The anesthesia was maintained by the administration of a 
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concentration of 1~2% halothane via a nose cone. During the course of the surgery, the 
halothane level was carefully adjusted to maintain surgical anesthesia as judged by the 
absence of pedal and tail reflex but presence of proper breathing pattern, heart rate and 
pink appearance of the paws.  
After a midline incision was made on the scalp, a craniotomy was performed on 
the right hemisphere overlying the M1 region of the cortex using a 5 mm diameter drill 
trephine centered at 1 mm anterior and 3 mm lateral to the bregma (-1.5 mm to 3.5 mm 
anterior and 0.5 mm to 5.5 mm lateral to bregma). Cool sterile saline was applied 
intermittently to prevent overheating from the high-speed drilling. After removing the 
piece of skull, the dura was carefully removed without damaging any of the cortical 
surface underneath or the overlying pial vessels. ET-1 (100 pmol/µl in saline) was 
applied to the exposed cortex in two 5 µl applications separated by an interval of 3 min, 
using a microsyringe. Three minutes later, another 10 µl was applied and the surface 
covered immediately with a piece of sterile gelfoam soaked with an additional 10 µl of 
ET-1. This was intended to slowly release the drug over the exposed cortex. A total of 
3,000 pmol ET-1 was applied. The opening in the skull was enclosed with a sheet of 
Parafilm® glued to the adjoining skull surface. Control animals were subjected to all of 
the procedures, except that ET-1 was replaced with sterile saline. 
3.2.2 Modified cortical devascularizing model ( Pial Vessel II 
Disruption Model) 
Adult male Wistar rats were anesthetized with an intraperitoneal injection of a 
ketamine (125 mg/kg) and xylazine (7 mg/kg) mixture. After surgical anesthesia was 
achieved, the rats were immobilized in a stereotaxic frame. The craniotomy was 
performed with a 5 mm diameter drill trephine positioned on the right and rostral side of 
the bregma adjacent to the coronal and sagittal sutures. Cool sterile saline was applied 
intermittently to prevent overheating from the high-speed drilling. After removing the 
dura, the cortical surface and the overlying pial vessels were exposed. Medium-size 
(class II) pial vessels, but not large ones (class I) (Bar, 1980) were disrupted using 
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fine-tip forceps (Fine Science Tools). Cool sterile saline was used to prevent bleeding 
before replacing the bone fragment. 
3.2.3 Wound Closure and Postsurgical Care 
The scalp was closed with a wound clip and buprenorphine (0.035 mg/kg) was 
injected subcutaneously for pain management. The body temperature was monitored 
throughout the surgery by a rectal probe and maintained at 37ºC with a heating pad. 
Animals were kept in separate cages, one animal per cage under a warm lamp during 
anesthesia recovery. 
3.3 Minocycline Treatment 
The minocycline regimen used was chosen based on data obtained from previous 
stroke studies on acute neuroprotection (Yrjanheikki et al., 1999). Due to the low 
solubility in saline, minocycline HCl (Sigma) was dissolved in sterile distilled water at a 
concentration of 15 mg/ml. Minocycline was stirred in distilled H2O, with heat as 
needed, until it yielded a clear, yellow to amber solution. The solution was stored at 4°C 
and protected from light.  
Minocycline was given intraperitoneally at a dose of 45 mg/kg 1 hour and 12 
hours after lesioning, followed by 22.5 mg/kg, given twice daily until 6 days after 
lesioning (Yrjanheikki et al., 1999). An equivalent amount of distilled water was used in 
controls. 
3.4 In Vivo Labeling of SVZ cells in Adult Rats 
To develop a reliable and reproducible method for in vivo labeling large amounts 
of SVZ cells, three methods have been used and tested in the normal and ischemic rat 
brain.  
3.4.1 BrdU Loading 
BrdU (5-bromo-2-deoxyuridine), a thymidine analog, is incorporated into newly 
synthesized DNA thus providing a marker for proliferating cells. BrdU (Sigma) was 
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administered intraperitoneally daily for two days at the concentration of 100 mg/kg, 
dissolved in 0.9% NaCl with 0.007 M NaOH. The first injection started 2 days prior to 
perfusion in the normal animal or prior to the induction of ischemic injury. An antibody 
directed against BrdU allows the identification of cells that have already incorporated 
BrdU, thus providing a marker for proliferating cells (see the immunostaining section for 
the detailed procedure). 
3.4.2 Retroviral Vector (RV)  
Retroviruses are known to infect predominantly proliferating cells. When such a 
virus is stereotaxically injected into the lateral ventricle, it will only be taken up by 
mitotic cells, such as neural precursor cells. The BAG replication-deficient RV was 
utilized to label proliferating subventricular cells in vivo as a non-diluting lineage 
marker. They carry the Lac-Z gene, which is responsible for coding the enzyme 
ß-galactosidase into a vector that was derived from the Moloney murine leukemia virus 
(Price et al., 1987). Briefly, RV was collected from confluent φ 2BAG alpha cells, 
supplemented with 1 µl/ml polybrene, filtered through a 0.45 mm filter, aliquotted and 
frozen at -80 ºC. The titer was 2.5 x 105 to 2.5 x 107 colony forming units. The retrovirus 
supernatant was kindly provided by Dr. Doucette (Department of Anatomy and Cell 
Biology, University of Saskatchewan), in whose laboratory all procedures were 
undertaken.  
I injected stereotaxically 2~4µl of RV supernatant into the lateral ventricle in the 
time period before the pial vessel disruption (AP = -0.7 mm, ML = 1.3 mm from 
bregma, DV = +4.7 mm from the skull). The injection rate was 0.5µl/min. The animals 
were sacrificed on day 4, 6 or 14. All the procedures involving handling of the retroviral 
supernatant were performed in accordance with requirements and standards of the 
Biosafety Code of the University of Saskatchewan (endorsed by the Board of Governors 
on March 29, 2001), the Laboratory Biosafety Guidelines (Laboratory Center for 
Disease Control, Health Protection Branch, Health Canada, Second Edition, 1996), as 
well as the policies of the Department of Health, Safety and Environment and the 
Biosafety Advisory Committee of the University of Saskatchewan. Use of the RV in 
these experiments was covered by Biosafety Permit #ANA-02. All of the in vitro work 
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using the RV was done in a Biosafety Level 2 hood in a designated biohazard room. 
3.4.3 Fluorescent Dye 
Two neural tracers, DiI and CFSE, were tested for their ability to label migrating 
cells in the SVZ. 
DiI ( Molecular Probes), a fluorescent lipophilic tracer, can passively diffuse 
across the plasma membrane. It fluoresces orange-red when viewed with a TRITC filter. 
DiI labeling does not appreciably affect cell viability, development, or basic 
physiological properties (Holmqvist et al., 1992). 2.5~5 µl DiI (0.25% in DMSO) were 
injected into different brain areas to test for the efficiency of labeling SVZ progenitor 
cells. 2.5~5 µl DiI was injected into the lateral ventricle (AP = -0.7 mm, ML = 1.3 mm, 
DV = 4.7 mm from bregma skull) and SVZa at four coordinates (AP = 0 mm, ML = 1.4 
mm, D = 4.8 mm from bregma skull; AP = 0 mm, ML = 1.4 mm, D = 4.6 mm from 
bregma skull; AP = 0.5mm, ML = 1.4, D = 4.8 from bregma skull; AP = 0mm, ML = 
1.5, D = 3.3 from bregma dura) lateral and deep. For the labeling in the PVD II rats, DiI 
was injected right before the induction of the PVD II at an injection rate of 0.5 µ l/min. 
The animals were sacrificed at different survival times, from 2 days to 2 weeks.  
Carboxyfluorescein diacetate, succinimidyl ester (CFSE, Molecular Probes) is 
also a lipophilic dye, which passively diffuses across the plasma membrane.  Unlike 
DiI, CFSE is colorless and nonfluorescent until it is transported into the cells, where its 
acetate groups are cleaved by intracellular esterases and then it yields highly fluorescent, 
amine-reactive carboxyfluorescein succinimidyl ester. The succinimidyl ester group of 
CFSE reacts covalently with intracellular amines, which enable CFSE to be 
well-retained in the cytoplasm.  The fluorescence is inherited by daughter cells after 
cell division, or cell fusion, and is not transferred to adjacent cells in a population (Li et 
al., 2003). Due to its instability, CFSE solution (in dimetheylsulfoxide) was made right 
before the in vivo injection. The fluorescein filter set was used to directly visualize 
CFSE labeled cells. 200 nl of 10 mM CFSE (500ug CFSE in 90 µ l dimetheylsulfoxide) 
was injected into SVZa (AP = 0 mm, ML = 1.4 mm, DV = 4.7 mm from bregma skull) 
at a speed of 0.1 µl/min. For the study of neuroblast migration after the ischemic injury, 
CFSE was injected either right before the induction of the PVD II or 2, 3 or 5 days after 
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PVD II. The rats were sacrificed at different survival times, from day 1 to 2 weeks.  
3.4.4 Craniotomy and Stereotaxic Injection 
Adult, male Wistar rats (270-330g) were anesthetized with ketamine and 
xylazine as described above. A small midline incision was made to expose the skull and 
the rats were then placed into the stereotaxic apparatus (Harvard Apparatus, ASI 
Instruments). The head was stabilized and adjusted with ear bars to obtain a flat skull 
position. A dremel with a 1 mm drill bit was used to drill a burr hole at the appropriate 
coordinates without damaging the dura and the underlying cortex.  
The stereotaxic injection was done using a  5  µl Hamilton syringe with a 
32-gauge needle attached to a microinjector. Three minutes after the needle was placed 
into the right position, the injection was started and it lasted 2 min. The syringe was left 
in place for an additional 3 min before a slow withdrawal was initiated to prevent any 
backflow. The scalp incision was closed with a suture.  
3.5 Histology and Immunocytochemistry 
3.5.1 FAM Fixed Paraffin-embedded Sectioning 
Rats were anesthetized with a ketamine (125 mg/kg) and xylazine (7 mg/kg) 
mixture as described above. For evaluating the ischemic animal models and assessing 
the neuroprotective effects of minocyline, FAM (formalin: acetic acid: methanol 1 : 1 : 
8) fixed paraffin-embedded sections were used. One, 3, 6, or 21 days after lesioning, rats 
were intracardially perfused with approximately 300 ml PBS (pH 7.4), followed by 300 
ml FAM solution. Brains were then removed and post-fixed in the same fixative 
overnight at 4°C. Brains were paraffin-embedded and cut into 10 µm thick coronal 
sections with a microtome. Sections were mounted on 3-amino-propyltriethoxysilane 
(APS)-coated (silanized) slides, dried at 37°C overnight and stored at room temperature. 
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3.5.2 4% PFA Fixed-Cryostat Sectioning 
FAM-fixed and paraffin-embedded sections were superior in reproducing 
morphological details of cells and immunostaining with some antigens, such as GFAP. 
To obtain better antigen preservation and thus to enhance immunostaining, especially for 
the neurogenesis and migration part of the project, 4% formaldehyde-fixed cryostat 
sections were used.  In brief, rats were intracardially perfused with 1% sodium nitrite in 
0.1 M PBS (sodium nitrite dilates blood vessels thereby helping to flush out the blood 
from the vascular system), followed by cold freshly depolymerized 4% formaldehyde 
(FA) in 0.1 M PBS (pH 7.4).  The brains were removed, post- fixed in 4% FA overnight 
and then moved into 30% sucrose solution and stored at 4°C before sectioning. Brains 
were embedded in Tissue-Tek optimal cutting compound (OCT; Sakura Finetek, 
Torrance, CA), frozen in liquid nitrogen-cooled isopentane and sectioned at 40 µm on a 
cryostat. Sections are mounted on the slides (Superfrost@ plus, VWR international) and 
stored at -20°C before labeling.  
3.5.3 X-Gal Staining of Tissue Sections  
X-Gal staining is used to detect β-galactosidase expression in the RV-infected 
cells. Nuclear Fast Red was used for high-contrast counterstaining. Tissue sections were 
incubated in a 0.1% x-Gal solution for 48 hours at 37°C and then submerged in 0.1% 
Nuclear Fast Red solution containing 5% ammonium sulfate for 2 min. Sections were 
then rinsed in phosphate buffer, dehydrated and coverslipped with Cytoseal 
(Richard-Allan Scientific). 
3.5.4 Lectin Histochemistry 
Lectin histochemistry was used to assess microglial / macrophage activation. 
B4-isolectin from Griffonia simplicifolia (GSAB4, Sigma) was used, as it specifically 
binds to alpha-D-galactosyl residues and labels all activation stages of microglia (Streit, 
1990). Deparaffinized sections were quenched with 0.3% hydrogen peroxide and 
pretreated in Citrate buffer (pH 6.0) at 90°C for about 45 minutes. After blocking in 1% 
bovine serum albumin, sections were incubated with biotin- labeled GSAB4 (10 µg/ml, 
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Sigma) in 1% bovine serum albumin (BSA) at 4°C overnight (Savchenko et al., 2000). 
Horseradish peroxidase (HRP)-conjugated streptavidin (1 µg/ml, Jackson Laboratories) 
was applied for 2 hours at room temperature. TRITC conjugated goat anti-HRP (1:25, 
Jackson Laboratories) was applied for visualizing the binding site. The nuclei were 
counterstained with Hoechst (see the following section).  
3.5.5 Immunofluorescence Staining 
Single and double- label immunofluorescence histochemistry was performed on 
paraffin-embedded or cryostat sections following a two-step immunofluorescent staining 
procedure. 
The sections were blocked in PBS containing 5% donkey serum and Triton 
X-100 (0.02% Triton X-100 for 10 µ m paraffin-embedded sections; 0.3% Triton X-100 
for 40 µ m cryostat sections) and incubated with primary antibodies overnight at 4ºC. 
The following primary antibodies were used: mouse anti-BrdU (1:200; Sigma-Aldrich), 
guinea pig anti-DCX (1:100, Chemicon), mouse anti-NeuN (1:100, Chemicon),  rabbit 
anti-GFAP (1:100, Sigma) or goat anti-GFAP (1:25, Santa Cruz), rabbit polyclonal 
antibody against Ki67 (1:200, Novocastra), rabbit polyclonal antibodies against MPO, 
(1:100, Neo Markers), mouse monoclonal antibody against rat CD3 (1:25, Serotec), 
mouse monoclonal antibody anti-neuronal class III β-Tubulin (TuJ1 clone, 1:500, 
Covance), mouse anti-polysialic acid-NCAM IgM (clone 2-2B, 1:300, Chemicon), and 
mouse anti-NG2 (1:100, Chemicon). Negative controls omitting the primary antibodies 
were carried out in all experiments for all the secondary antibodies used.  After 
washing in PBS, sections were incubated with secondary antibodies conjugated with 
fluorescence dyes (TRITC, FITC) at room temperature for 2 h in blocking solution 
without Triton X100. The secondary antibodies included donkey anti-guinea pig IgG 
conjugated to TRITC or FITC, donkey anti-mouse IgG conjugated to FITC or TRITC, 
donkey anti-rabbit IgG conjugated to FITC or TRITC, donkey anti-mouse IgM 
conjugated to FITC or TRITC and goat anti-mouse IgG conjugated to FITC or TRITC. 
All secondary antibodies were used at 1:100 or 1:200 dilutions, and were species 
cross-adsorbed from Jackson Immunoresearch Laboratories (West Grove, PA).  
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Sections were rinsed three times in PBS and coverslipped with anti- fade 
mounting medium (Citifluor glycerol/PBS, Marivac). Paraffin-embedded sections went 
through deparaffinizing and rehydrating steps before the immunostaining procedure was 
applied. For nuclear counterstain, sections were incubated with Hoechst 33243 (1 µg/ml) 
for 15 min. They were washed three times in PBS before coverslipping.   
Heat- induced antigen retrieval (AR) technique was used in GSAB4 
histochemistry and MPO, CD3, DCX and Ki67 immunostaining. This allowed for the 
retrieval of antigens that had been masked by formalin fixation (Boenisch, 2001). The 
slides were immersed in citrate buffer (pH 6.0) at 90oC for about 45 minutes to 1 hour. 
This resulted in a stronger intensity of the immunohistochemical staining.  
3.6 Assessment of Lesion Volume and Cystic Cavity 
By day 6, the cortical devascularizing lesion was filled with cellular material 
(mostly macrophages and microglia) and had a distinct border. By day 21 it turned into a 
fluid-filled cyst with a glia limitans. Thus, a well-demarcated cortical lesion was 
observed by day 6 and a cystic cavity developed at 21 days. The quantification of the 
lesion volume was achieved by hematoxylin and eosin (H&E) staining on 6 days 
post-surgery animals. Every tenth section of a series of 10 µm-thick sections was stained 
with H&E. The sections were captured by digital camera (Coolsnap fx) mounted on a  
microscope (Olympus IX71) and the border traced on the electronic image. The lesioned 
area on each section was computed from the border outline using ImagePro software. 
The total lesion volume was calculated by summation of the areas multiplied by the 
interslice distance (100 µm). 
The fluid-filled cystic cavity appeared between day 14 and 21. It was evident 
from the cell- free area encased by a glia limitans (Wang and Walz, 2003; Wang et al., 
2004) and did not need any staining in order to be recognizable. As minocycline 
completely prevented the appearance of such a cell- free space (see Results) and resulted 
in a cavity space of zero, quantification and statistical analysis was not necessary for the 
experiments dealing with cavitation. 
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3.7 Enzyme-linked Immunosorbent Assay for IL-1β 
Twenty-four hours following PVD II, the rats were perfused with ice-cold PBS 
and the ischemic ipsilateral and non- ischemic contralateral cortices were removed, snap 
frozen in liquid nitrogen and stored at -80°C until assayed. For extraction of proteins, the 
tissue was homogenized in 250 µl of homogenization buffer consisting of: 50mM 
Tris-HCl, pH 7.3, 5mM EDTA, 1% protease inhibitor cocktail (Sigma, P8340) for every 
50 mg wet weight. The samples were centrifuged at 4oC for 20 min at 13,000 RPM and 
the supernatant was aliquotted. The IL-1β protein concentrations in rat brain tissue 
homogenates were quantified using ELISA Duoset kits (R&D Systems). Initial studies 
showed that IL-1β recovery from brain tissue spiked with known concentrations of 
IL-1β was in the range of 85%-120%. Tissue extracts (100 µl) were applied to each well 
for the ELISA and all the samples were in duplicate. IL-1β protein concentrations were 
normalized based on the original wet weight of the brain tissue samples. 
3.8 Cell Counting and Image Analysis 
The images of stained specimens were captured by a photometrics CoolSnap fx 
CCD camera mounted on a microscope (Olympus IX71) and analyzed with Image-Pro 
Plus software (Version 4.5). Cellular co-localization was confirmed using confocal 
microscopy (Zeiss, LSM-410). Single confocal images were taken as 1 µm optical 
sections from 40 µm cryostat sections. All tissue sections to be used for cell counting 
were counterstained with Hoechst prior to mounting to ensure that the only positive 
profiles counted were those associated with a nucleus. 
Microglial/macrophage activation was assessed at 6 days post lesioning based on 
GSAB4 histochemistry on 10 µm paraffin-embedded sections. For quantification, at least 
3 sections per area of interest were stained and counted from each animal. Only GSAB4+ 
cells with nuclei were counted for the peri- infarct areas. Cell population density was 
calculated by dividing the cell number by the brain section volume. The results were 
corrected with the use of Abercrombie's technique, allowing assessment of the real 
density of microglia (Savchenko et al., 2000). The calculation was carried out using the 
formula: N= n × T / (T + D), where N is the estimate of the true cell number, n is the 
number of nuclear segments, T is mean section thickness and D corresponds to a mean 
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nuclear diameter. The number of MPO-positive cells in the entire lesion was counted 
and normalized to the area of infarct.  
DCX+ cell counting was performed on 40 µ m-thick PFA-fixed cryostat sections. 
For quantification of the DCX+ cells, three to six parasagittal sections through the lesion 
(1.4~2.4 mm lateral to the bregma) were examined.  DCX + cells in the cortex 
surrounding the injury, between the injury and corpus callosum and i n  the corpus 
callosum were quantified. Only DCX+ cells with a nucleus were counted. DCX+ cells 
(TRITC filter) were identified at 20X magnification, the filter was then switched to view 
Hoechst 33243 in order to determine if the cells were Hoechst+. A higher magnification 
(40X) was used to confirm that DCX and the nucleus were in the same cell by focusing 
up and down through the cell volume and ascertaining that cytoplasmic DCX 
immunoreactivity completely enveloped the nucleus. Results were expressed as the 
average number of DCX+ nuclei per 40 µm cryostat section between the lesion and 
RMS.  
3.9 Statistical Analysis 
All values are expressed as the mean ± standard error of the mean (SEM). The 
significance level was set at P < 0.05. Paired two-tail t-test was used to investigate 
significant differences between control and experimental groups regarding the lesion 
volume, the numbers of microglia/macrophage cells, MPO cells and body weight. For 
statistical analysis for IL-1β protein concentrations, the two-way analysis of variance 
[ANOVA] was used with ischemic- and drug-treated animals as the two variables. The 
one-way ANOVA was used to compare the number of DCX+ cells in experimental rats 
to control rats with days post- ischemia being the independent variable; the numbers of 
DCX+ cells in corpus callosum and neocortex was analyzed separately for statistical 
significance. Multiple post hoc comparisons between the different Groups were 
performed with Bonferonni’s multiple comparison post-test with the significance level 
being set at p < 0.05. 
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4. VALIDATION OF AN APPROPRIATE FOCAL 
ISCHEMIA MODEL IN ADULT RATS  
4.1 Introduction 
There are a number of rodent focal ischemia models but the most commonly 
used involve occlusion of the MCA. The use of this model results in a substantial lesion, 
which encompasses the neocortex as well as the striatum . However, malignant human 
stroke (brain infarction >200 cm3, or 39% of  the ipsilateral brain hemisphere)  i s 
observed only in 10% of the cases (Carmichael, 2005). Many human strokes are of small 
size and of lacunar nature (Carmichael, 2005). This is a type of small vessel stroke, 
which constitutes approximately 25% of first ischemic strokes  i n humans (Lammie, 
2000). If only the large size stroke animal models were used, this would lead to a 
potential bias against the clinical situation (Carmichael, 2005). There is an urgent need 
to focus on more research of the small vessel brain disease variety, which is the one 
prevalent in silent strokes and gives rise to cavitation (Greenberg, 2006).  
In rodents, small size infarction in the motorsensory cortex has been induced by 
different techniques, such as photothrombosis, ET-1 injection, or devascularization. As 
reviewed in Section 1.4, all animal models have advantages and disadvantages. The 
traditional pial vessel disruption model, often referred to as the devascularization model 
or pial stripping model, was induced by complete termination of all the vessels overlying 
the exposed cortex (Funnell et al., 1990; Fedoroff et al., 1997; Conner et al., 1998; Farr 
and Whishaw, 2002; Gonzalez and Kolb, 2003; Kolb et al., 2006). This model most 
often results in a massive rectangular cortical infarct, extending far into the corpus 
callosum, and it creates hemorrhage due to stripping off the large class I vessels (Bar, 
1980). The drawback of this model is that it mimics neurotrauma rather than ischemia 
due to its massive impact. In order to avoid these problems, the devascularizing model 
has been modified in our lab
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and a rat model developed that is initiated by disruption of the medium size pial vessels 
(class II) only (Bar, 1980).  This modified cortical devascularizing model (called pial 
vessel II disruption model) was applied to a smaller brain surface, a 5 mm circular area 
overlying the motor cortex. Instead of scraping off all the pial vessels in the exposed 
area with a mechanical device, a pair of fine forceps was used to disrupt the tip of 
medium size pial vessels (class II) only to minimize the mechanical damage. This 
modified method introduces a small cone shaped cortical lesion, with the tip often 
reaching into layers IV and V of the cortex. The tip never reaches deep enough to touch 
the corpus callosum. After two weeks, cavitation develops at the site of the lesion (Fig 
4-1) (Wang and Walz, 2003). 
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Figure 4-1. H&E stained sections illustrating the development of the lesion following 
PVD II. The insertion in A illustrates the typical PVD II lesion and sections were from 
the area depicted by the shaded box. A: 1 day, B: 2 days, C: 3 days, D: 6 days, E: 21 
days, F: same animals as E but stained for GFAP. The lesion turns into a fluid filled 
cystic cavity surrounded by the glial limitans by day 21. Scale bar: 300 µm applies to all 
sections (from Wang and Walz, 2003). 
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PVD II mimics irreversible focal ischemia. Permanent occlusion of blood vessels 
has proved a useful model but the persistence of the occlusion differs from occlusion 
stroke in humans, where reperfusion frequently occurs (after a variable time) in a high 
proportion of patients (Carmichael, 2005). We therefore compared the PVD II model 
with a similar, but reversible model.  
ET-1 is a 21 amino acid peptide with potent vasoconstrictor properties (Reid et 
al., 1995). Direct injection or topical application of ET-1 to the brain tissue or to the 
middle cerebral artery revealed a reversible vasoconstriction of the artery that resulted in 
profound reductions in local cerebral blood flow and the development of cerebral 
infarction (Robinson et al., 1990; Macrae et al., 1993; Fuxe et al., 1997). In order to be 
comparable to the PVD II model, ET-1 was topically applied to the exposed cortical 
surface area. The purpose of this section is to examine whether this model, which allows 
reperfusion, is superior to PVD II. If successfully reproducible, it would offer a simple 
model with the advantage of combining primary focal cerebral ischemia with a 
secondary phase of reperfusion.  
4.2 Results 
27 adult male Long Evans rats were used to evaluate the topical ET-1 
application model. All rats tolerated the surgical procedure well and there was no 
mortality due to the surgery. Rats were sacrificed 1 (n=5), 3 (n=13) and 6 (n=9) days 
post surgery and every tenth section of a series was stained with Harris hematoxylin and 
eosin (H&E) to identify the lesioned area as well as gliosis. Following surgery, the 
majority of animals (24 out of 27) developed a complete bowl-shaped infarct, which was 
confined to the sensorimotor cortex as judged by histological assessment. The depth of 
the lesion varied among the animals, extending from the cortical surface ventrally to 
different layers or even to the corpus callosum (Fig 4-2, A, B, C). As shown in the 
figures, the typical lesion appeared to cross right through the neocortex. In 
approximately 50% of the rats, the lesion also extended into the corpus c allosum. 
However, direct subcortical structural damage, such as in the striatum, was not evident. 
In a small set of rats (3 out of 27), a complete cortical infarct did not form or was in a 
completely irregular shape as judged by H&E staining.  
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The developing infarct shows a progression of pathological events similar to 
those observed in the PVD II model (Wang and Walz, 2003). As determined by H&E 
staining, a cortical infarct was apparent one day after topical application of ET-1. 
Neurons appeared angulated and slightly shrunken (Fig 4-2, D). By one day neurons 
with shrunken nuclei and hypereosinophilic cytoplasm were evident within and 
surrounding the lesions. On day 3, most of the neurons in the lesion were gone and the 
lesion was surrounded by a rim of activated microglia/macrophages that had begun to 
infiltrate the lesion area (Fig 4-2, E). A well-demarcated infarct was formed at day 6, 
surrounded and filled with a rim of activated microglia/macrophages (Fig 4-2, F).  
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Figure 4-2.  Distribution of cortical infarction and the development of the lesion 
induced by the topical ET-1 application model. Paraffin-embedded sections of H&E 
staining at different magnifications, showing representative lesions at 1 day (A, D), 3 
days (B, E) and 6 days (C, F) after topical application of ET-1 onto the pial surface. The 
white outlines represent the extent of the cortical infarct. Higher magnification views of 
the infarct showed the histopathological changes in the lesion at 1 day (D), 3 days (E) 
and 6 days (F) after topical application of ET-1. Scale bar: 500 µm (A, B, C), 50 µm (D, 
E, F).  
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The occlusion and reperfusion of the brain surface vasculature therefore resulted 
in a progressive infarction in a small cortical volume of a large percentage of animals. 
However, it also introduced a variety of anatomical distortions into the brain tissue. The 
damaged tissue was swollen, so that it frequently protruded out of the skull. In some 
cases, the caudate-putamen was also distorted and pushed upward. In some rats it 
resulted in substantial brain edema (Fig 4-3).  There was no obvious cortical neuron 
damage or brain edema observed in sham animals. Table 4-1 represents a summary of 
the degree of brain damage observed in each time point following topical ET-1 
application.  
 
 
Figure 4-3. Images of H&E-stained 10 µ m -thick coronal brain sections at the level of 
the largest lesion extension, six days after topical application of ET-1. A: Representative 
section shows no obvious edema of the ipsilateral hemisphere and there is no blood on 
the brain surface indicating no submeningeal bleeding. B: Representative section shows 
severe pulling up of tissue in the wound area, edematous tissue is observed in the 
damaged area.  C: The edematous tissue along the hematoma is evident. 
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Table 4-1. A summary of the degree of brain injury observed at each time point 
following topical ET-1 application.  
 
 Day1 (n=5) Day3 (n=13) Day6 (n=9) 
Irregular shape lesion/incomplete infarct 1 1 1 
Lesion without tissue protrusion 1 3 4 
Lesion with medium tissue protrusion  1 5 3 
Lesion with severe tissue protrusion 2 4 1 
Hematoma observed in damaged tissue 3 3 4 
 
The numbers were the numbers of rats in each category. The degree of tissue protruding (no, medium, severe) was 
determined under microscopy. 
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4.3 Discussion 
For the study of the pathology and potential therapeutic strategies of cerebral 
ischemia, it is crucial that reproducible in vivo animal models are used. In the past, most 
focal cerebral ischemic investigators have used the various MCAO models. However, as 
pointed out above, there is a real need for models reproducing aspects of small-vessel 
occlusion. Most human strokes are small in size and the massive infarctions, also called 
malignant hemispheric infarctions, o n l y  account for about 1 0 %  of human strokes 
(Carmichael, 2005). Using only large size stroke models induces a potential bias against 
smaller stroke types.    
In this study, I have demonstrated that the topical application of ET-1 to the pial 
surface results in ischemic damage to the underlying cortical gray matter in a high 
percentage of the cases, therefore providing a useful technique for inducing cortical 
ischemic injury. However, tissue deformation and brain edema were observed in many 
animals. The occurrence of brain edema, tissue deformation and hemorrhage makes this 
model inappropriate for studying neuroprotective agents. The impact of treatment on 
infarct volume is difficult to judge. The tissue deformation due to edema makes the 
accurate measurement of a relative small lesion volume very difficult and will result in 
inaccurate measurements. Another disadvantage of the ET-1 model is that ET-1 and both 
subtypes of the ET-1 receptor are found not only on endothelial cells, but also on 
neurons and astrocytes (Reid et al., 1995). It has been reported that ET-1 application 
induces astrocytosis (Hama et al., 1997), cortical spreading depression (Dreier et al., 
2002) and that it affects gap junction permeability (Sanchez-Alvarez et al., 2004). These 
findings suggest that ET-1 exerts a direct, receptor-mediated signaling effect on 
astrocytes and neurons that may exacerbate the ischemic damage and complicate the 
interpretation of therapeutic or neural repair experiments. 
The associated occurrence of the brain edema and distortion of the cortex and 
basal ganglia suggested that ipsilateral brain edema was occurring. Indeed, the dosage of 
ET-1 used in this study is higher than the dose used in some other studies (Fuxe et al., 
1997; Adkins-Muir and Jones, 2003). The high dosage of ET-1 may have induced 
prolonged reductions in cerebral blood flow. Delayed reperfusion can induce increases 
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in vascular permeability during reperfusion, which aggravates brain edema formation, 
especially the vasogenic component, and parenchymal hemorrhages (Siesjo, 1992b; 
Schaller and Graf, 2004).  Disruption of the BBB after reperfusion has been observed 
with transient MCAO, but not after permanent MCAO (Kastrup et al., 1999) and the 
disrupted BBB is known to  contribute to vasogenic edema (Dietrich et al., 1987b; 
Kimelberg, 1995). It has also been reported that ET-1 induced focal cerebral ischemia is 
associated with acute but reversible hemispheric swelling during the early phase of 
reperfusion (Gartshore et al., 1997) and this early swelling might worsen and contribute 
to tissue deformation. A lower dose of ET-1 may be all that is needed to produce a 
consistent cortical lesion and yet reduce the brain edema and tissue protrusion.  
Another possible cause for the anatomical distortion / histological changes might 
be the location of the lesion. In this model, the lesion was placed right on top of the 
lateral ventricle, therefore, the removing of the skull and tissue damage right above the 
lateral ventricles may result in pressure that gradually will push the tissue up. Even more 
extensive brain distortion was reported in a cortical lesion placed on the cortex right 
above the lateral ventricle and induced by wiping off all the pial and blood vessels as 
well as the suctioning o f f 1 o f  mm3 pieces of brain tissue (Whishaw, 2000). It is, 
however, noteworthy that more laterally (Adkins-Muir and Jones, 2003; Luke et al., 
2004) or  more caudally (Fuxe et al., 1997) placed lesions have not been reported to 
produce similar degrees of tissue distortion. Indeed, in the PVD II model, the lesion is 
placed 1.5 mm anterior as compared to this injury and the damaged tissue upswelling 
and protruding was observed only rarely.   The profound local tissue upswelling limits 
this model in its application to the study of neuroprotection after stroke. 
In summary, topical administration of ET-1 (3,000 pmol) to the pial surface 
induces, in most of the animals, a pan-necrotic infarct by day 1 and a well-defined 
infarct surrounded by a rim of microglia/macrophages by day 6. Wang and Walz (2003) 
established the development of histological damage in the PVD II model. In comparison 
with the PVD II model, the topical ET-1 application model also provides a cortical 
infarct with precise injury location and a high reproducibility. It therefore provides a 
good model of the mechanistic aspects of focal ischemia. Indeed, vascular damage 
caused by prolonged cerebral ischemia can lead to brain edema and hemorrhage 
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formation in ischemic stroke patients (Fagan et al., 2004a). Therefore, the topical ET-1 
model incorporates some useful conditions that may be observed in human ischemic 
stroke, e.g., brain edema, bleeding, or reperfusion. Therefore, it provides a useful model 
to study the mechanisms involved in ischemic pathology and neural repair. However, the 
occurrence of brain edema and tissue protrusion complicates the volume estimation of 
ischemic lesions because the entire affected hemisphere (still containing non-affected 
tissue) may be swollen and enlarged compared to the contralateral side, which results in 
inaccurate measurements. In addition, the existence of the edematous damaged area 
makes the accurate measurement of a relatively small lesion volume very difficult.  As 
the infarct volume is a major parameter for neuroprotective evaluation this model needs 
further improvement. 
 The PVD II model creates a consistent and reproducible cortical injury with 
very rare occurrence of tissue protrusion and upswelling (Wang and Walz, 2003; Wang 
et al., 2004). It should be noted that the lesions produced by PVD II were smaller than 
those in  many studies of the effects of “focal” cortical damage, especially the 
photothrombosis model, ET-1 model (intracerebral injection and topical application) and 
the traditional cortical devascularization model with class I vessel disruption (Fig 4-4). 
Instead of scraping/tearing off all pial vessels in the exposed area, the big vessels, which 
supply the white matter (Bar, 1980) are salvaged, and the medium pial vessels are 
disrupted by using fine forceps to minimize the mechanical damage and subsequently 
bleeding. This prevents hemorrhage and causes a cone shape lesion exclusively located 
in the cerebral cortex. As with all models of ischemia there are disadvantages and 
advantages with using the PVD II model for studying neuroprotective agents. This 
model creates a pure cortical injury, small in size and allows the flexibility of changing 
the injury site, which mimics small-vessel stroke in the clinic. The disadvantages stem 
from the mechanical disruption of the vessels although there is no obvious damage in the 
control animals as evidenced by microscopic observation (Wang and Walz, 2003).   
Obviously, this model causes an irreversible interruption of blood flow and therefore 
appears not to take into account reperfusion. However, about 80% of reperfusion in 
human stroke is not through clot lysis, but through collateralization (Carmichael, 2005). 
Collateralization will not be affected in this PVD II model. It has been suggested that a 
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permanent ischemic model should be used to test the efficacy of potential 
neuroprotective drugs to enhance clinical success (Richard Green et al., 2003). On  
balance, I decided to use the PVD II model for the assessment of the potential benefits of 
minocycline.  
 
  
Figure 4-4. Schematic drawing of lesion sizes in three 
different stroke models. The typical lesion in the 
coronal brain sections wi th  the corpus callosum and 
lateral ventricles (dotted lines) in the PVD II model (A), 
conventional pial vessel disruption model (B) and 
topical ET-1 model (C). A: PVD II model introduces a 
small cone-shape cortical lesion. The tip never reaches 
deep enough to touch the corpus callosum.  B :  
conventional pial vessel disruption model results always 
in a massive rectangle cortical infarct, extending far into 
the corpus callosum. C: the topical ET-1 model induces 
a bowl-shaped infarct. The depth of the lesion varied 
among the animals. In 50% animals, the lesion reaches 
into the corpus callosum.  
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5. ASSESSMENT OF THE NEUROPROTECTIVE EFFECT 
OF MINOCYCLINE IN A PIAL VESSEL II DISRUPTION 
MODEL 
5.1 Introduction 
Minocycline, a second-generation tetracycline, has been shown to have 
neuroprotective properties in animal models of acute CNS injury and chronic 
neurological diseases (reviewed in section 1.3.1.2). A heterogeneity of beneficial effects 
have been proposed: anti- inflammation, anti-apoptotic, anti-oxidant and a paucity of 
negative side effects as well (Domercq and Matute, 2004; Stirling et al., 2005). With 
regards to stroke, minocycline showed beneficial effects in different animal models of 
global ischemia (Yrjanheikki et al., 1998; Yrjanheikki et al., 1999), transient and 
permanent focal cerebral ischemia (Yrjanheikki et al., 1999; Xu et al., 2004; Koistinaho 
et al., 2005), intracerebral hemorrhage m o d e l  (Power et al., 2003) a n d   
hypoxic-ischemic brain injury in neonatal rats (Yrjanheikki et al., 1999; Arvin et al., 
2002; Fox et al., 2005). However, there are also contradictory results showing that 
minocycline has no beneficial effects (Fox et al., 2005) or even that it exacerbates injury 
(Tsuji et al., 2004). In a permanent MCAO in adult mice, if minocycline treatment was 
started before the insult, the drug reduced the infarct size, whereas if the treatment was 
started after the insult, minocycline was not protective (Koistinaho et al., 2005). Before 
minocycline can be used in clinical trials with stroke patients, it must be shown to be 
effective in several types of stroke models with drug delivery times that are clinically 
realistic (Diguet et al., 2004a; Yong et al., 2004). To date, the dominant model used in 
studying minocycline actions is the MCAO model. If only the large size stroke animal 
models are used, this will lead to a potential bias against the clinical situation 
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(Carmichael, 2005). Therefore, in the present study, the PVD II model was used to test 
the effects of minocycline treatment. Standard minocycline treatment was started an 
hour after lesioning and the outcome was evaluated based on histological and 
immunohistochemical parameters. 
5.2 Results 
5.2.1 Minocycline Treatment Prevents Formation of the Cystic Cavity 
and Glia Limitans 
The PVD II model was applied to adult rats with or without minocycline 
treatment. One day after injury, the damaged area was identified as less densely stained 
with dying neurons present, which lack stainable nucleic acid. After 3 days all cells 
(neurons and non-neuronal cells) in the lesion disappeared. Microvessel proliferation 
and a massive infiltration of blood-borne cells was observed in the infarct area. A 
well-demarcated cortical lesion was observed by day 6 and a cystic cavity developed by 
21 days (see Fig 4-1) (Wang and Walz, 2003). 
Since the lesion developed a distinct border by day 6, day 6 was chosen as the 
time point to measure the volume of the cortical lesion from the H&E stained sections. 
Minocycline treatment did not reduce the lesion volume (1.09 ± 0.30 mm3) compared to 
the control group (injected with equivalent amount of distilled H2O, see Materials and 
Methods Section 3.3) (0.91 ± 0.15 mm3, n=6) (Fig 5-1). However, by day 21, in the 
minocycline-treated group, only 1 out of 6 animals had developed a cavity in contrast to 
5 out of 6 animals in the control group that exhibited a cystic cavity in the lesion area 
(Fig 5-2 A, B).  
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Figure 5-1. Lesion volume 6 days after PVD II in control and minocycline- treated rats 
as measured with H&E (n=6). There is no significant difference (P=0.63). Data are 
shown as mean ± SEM. 
 
 
 
The cystic cavity is surrounded by a glia limitans (Wang and Walz, 2003). Since 
minocycline treatment prevented the cavitation, this study investigated whether the 
rescued tissue is part of the brain parenchyma and therefore within the tissue enclosed 
by the glia limitans, or outside the glia limitans.  GFAP immunostaining was therefore 
used as a marker of astrogliosis. In the control group all animals developed a glia 
limitans on day 21 following injury (Fig 5-2 A, C). With minocycline treatment, the glia 
limitans was absent in 5 out of 6 treated rats (Fig 5-2 B, D) and the rescued tissue space 
was filled with reactive GFAP+ astrocytes (Fig 5-2 D). However, the appearance and 
distribution of GFAP+ cells in the tissue surrounding the lesion is not changed by 
minocycline treatment on days 1, 3 and 6 after injury (Fig 5-3). 
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Figure 5-2.  Effect of minocycline on cystic cavity and glia limitans 21 days after PVD 
II. A cystic cavity and glia limitans developed between days 14 and 21 in the control 
group (n=6; A, C). With minocycline treatment, the glia limitans was absent and the 
injured area was filled with reactive GFAP+ astrocytes (n=6; B, D).  A, B: 
Representative H&E stained sections.  C, D: Adjacent sections stained for GFAP. Scale 
bar: 200 µm.  
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Figure 5-3. Comparison of GFAP staining in control (A, C) and minocycline treated rats 
(B, D) six days after PVD II. A, B: The overview pictures include cortical lesion and 
peri- lesion areas. White outline delineates the lesion. C, D: high magnification of the 
square outlined areas in A, B. Scale bar: 500 µm (A, B); 50 µm (C, D). 
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5.2.2 Minocycline Treatment and Inflammatory Response after Pial 
Vessel Disruption 
5.2.2.1 Microglia Activation 
There is evidence that the neuroprotective effect of minocycline is related to the 
inhibition of microglial activation (Tikka et al., 2001). To determine whether 
minocycline affects glial cell activation, lectin histochemistry was used to determine the 
microglia morphology. Microglia were identified by means of lectin histochemistry with 
B4-isolectin from Griffonia simplicifolia (GSAB4, Sigma), which specifically binds to 
alpha-D-galactosyl residues. It stains microglia during all stages of activation (Streit, 
1990). The following classification was used to describe the stages of microglial 
activation (Ziaja and Janeczko, 1999; Kato and Walz, 2000).  
1. Resting microglia, which are ramified microglia and present in the normal brain. They 
have round, small cell bodies with radiating long, thin, branched processes.  
2. Activated microglia, which are cells responding to ischemia with morphological and 
immunophenotypic changes, but which are not phagocytic. Their morphological changes 
include enlarged cell bodies and contraction of their processes to show a more stout 
morphology. Two major morphological types were detected in this model: a highly 
ramified shape, with an enlarged cell body giving rise to ramified tapered process; a 
bushy shape, a very large cell body with thick, short processes.  
3. Phagocytic microglia, which are full-blown brain macrophages with an amoeboid or 
round morphology, a n d  with expression of a number of immunomolecules that are 
shared with hematogenous macrophages.  
As described in detail in Methods and Materials, microglial activation after PVD 
II is classified into 3 stages/types: resting microglia, activated microglia, and phagocytic 
microglia/macrophages. The typical morphology of these three types/stages of GSAB4+ 
microglia in the control group is shown in Fig 5-4.  
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Figure 5-4. The typical morphology of three types/stages of GSAB4+ microglia after 
PVD II. A: Resting microglia in the cerebral cortex of normal brain, which showed 
ramified morphology; B-C: Activated microglia: morphological changes of activated 
microglia include enlarged cell bodies and contraction of processes. Two major 
morphological types were detected in this model: highly ramified shape (B, enlarged cell 
body giving rise to ramified tapered processes; day 1 post lesion; peri- infarct) and a 
bushy shape (C, very large cell body with thick, short processes; day 3 post lesion; 
peri- infarct) D: Phagocytic microglia demonstrating an amoeboid or round brain 
macrophage- like morphology (day 6 post lesion; infarct). Scale bar: 20 µm. 
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In the control group, one day after injury, scattered GSAB4 positive small round 
cells were present in the affected area, but no resting and activated microglia could be 
seen there. In the area surrounding the infarct core, bushy and highly ramified cells were 
seen in increasing numbers. The activation and proliferation of microglia were further 
increased on day 3. Accumulated round and amoeboid cells were present within the 
infarct. A dense zone of bushy microglia mingled with amoeboid cells was observed 
between the infarct and the surrounding area thus forming a transitional zone. 
Surrounding this transitional zone, most of the microglia were highly ramified. After 6 
days, the entire ischemic core was densely covered by round and amoeboid cells. The 
transitional zone was very narrow compared to day 3. Highly ramified cells mixed with 
bushy cells were seen immediately surrounding the infarct core. The density of the 
GSAB4 positive cells in the surrounding area was doubled compared to the contralateral 
area, from 14,095 ± 438 to 27,088 ± 4,291 cells/mm3 (P<0.05; n=3), indicating a robust 
activation of microglia after PVD II. In the minocycline-treated group, neither the 
morphology and distribution of the activated types nor their densities were changed 1, 3 
and 6 days following ischemia (Fig. 5-5). The density of activated microglia surrounding 
the infarct core was further quantified on day 6 in the minocycline treated group. 
Minocycline did not change the density of GSAB4 positive cells in the contralateral 
brain: 13,798 ± 1,621 cells/mm3 in the minocycline-treated group and 14,095 ± 438 
cells/mm3 in the control group. The density of GSAB4 positive cells in the area 
surrounding the infarct showed no significant difference between the 
minocycline-treated group (23,610 ± 1,067 cells/mm3) and the untreated group (27,088 ± 
4,291 cells/mm3; Fig 5-5, G) as well. These results indicated that minocycline treatment 
did not alter the activation of microglial phenotypes.  
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Figure 5-5. Comparison of GSAB4 staining in the infarct and peri- infarct area of control 
group (A, B, C) and minocycline-treated group (D, E, F) at different time points. A, D: 
day 1; B, E: day 3 and C, F: day 6. In the minocycline-treated group, neither the 
morphological activation of microglia nor density was changed 1, 3 or 6 days following 
ischemia.  White outlines delineate the lesion. The small picture insets represent high 
magnification of the rectangular outlined areas. Scale bar: 300 µm. G: Quantitative 
comparison of GSAB4+ cells in the different areas surrounding the lesion on day 6 in 
control group and minocycline-treated group. The inset represents a coronal section with 
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locations of the ischemic lesion and representative fields used in quantification. The 
two-way ANOVA was applied to the data for statistical significance. Multiple post hoc 
comparisons were performed with Bonferonni’s multiple comparison post-test. The 
two-way ANOVA showed only a significant main effect of distance from the lesion on 
GSAB4+ cell density, F(2,12)=26.30, P<0.0001). There was no significant main effect of 
the minocycline treatment. Bonferonni’s post-test revealed the cell density was 
significantly ( P<0.05, white bar vs. black bar) increased in the areas immediately 
surrounding the lesion compared with the contralateral area in both control and 
minocycline-treated groups. Bonferonni’s post-test also revealed a significant increase 
of cell density in the areas immediately surrounding the lesion compared with the remote 
area ( P<0.05, white bar vs. grey bar) in the control groups.  
 
5.2.2.2 Infiltration of Leukocytes and T-lymphocytes 
Only few infiltrating leukocytes, predominately polymorphonuclear neutrophils 
(PMNs), determined by myeloperoxidase (MPO) immunoreactivity, were detected in 
either the contralateral side or the tissue outside the lesion of the ipsilateral hemisphere. 
The MPO immunoreactive cells were evident in the lesion site at day 1 and day 3 after 
PVD II (Fig 5-6 A, B) and only occasionally seen in the lesion site at day 6.  
Quantitative analysis showed that minocycline treatment did not significantly reduce the 
invasion of PMNs (Fig 5-6 C). Only very few infiltrating T- lymphocytes (CD3 
immunoreactive cells) were seen around the border of the lesion site on day 1. At day 3, 
their numbers had increased, and reaching a peak around day 6. The infiltration of CD3 
immunoreactive lymphocytes was not affected by minocycline treatment (data not 
shown).  
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Figure 5-6. Infiltration of neutrophils after PVD I I . (A, B) Photomicrographs of 
myeloperoxidase- immunostained neutrophil infiltration in lesion 1 day (A) and 3 days 
(B) after PVD II. The white outline indicates the border of the infarct zone. (C) Number 
of polymorphonuclear neutrophils in the lesion at day 1 and day 3 after PVD II. 
Myeloperoxidase-positive cells were normalized with the lesion area. Minocycline 
treatment did not reduce the number of polymorphonuclear neutrophils in the lesion 
(n=3). Scale bar: 100 µ m . 
 
5.2.2.3 Interleukin-1β Protein Expression 
The amount of IL-1β in the tissue extract was expressed as ng/g wet weight of 
the samples. The PVD II resulted in a significant increase in the IL-1β concentration of 
injured brain tissue compared to the contralateral side (Fig. 5-7). The significant increase 
of IL-1β was primarily due to the large increase seen in the control groups since the 
post-test revealed no significant difference between the levels measured in the ischemic 
lesion vs. the contralateral side in minocycline-treated groups. This suggests the 
minocycline treatment reduced the IL-1β expression induced by ischemic injury, 
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although this reduction was not large enough to reach statistical significance. IL-1β 
concentration was also normalized to the total sample brain protein. Both ways of 
expressing the data showed similar results. 
  
 
 
 
Fig 5-7. ELISA analysis of IL-1β expression in the brain after PVD II.  The data are 
expressed in ng/g wet tissue weight. Two-way ANOVA was applied to the data for 
statistical significance. Multiple post hoc comparisons were performed with 
Bonferonni’s multiple comparison post-test. The two-way ANOVA only revealed a 
significant main effect of the ischemia on the IL-1β level, F(1,24)=6.37, P<0.019; The 
main effect  of minocycline treatment failed to reach statistical significance, 
F(1,24)=2.66, P=0.12. The two-way ANOVA revealed no significant interaction 
between the lesion/no lesion and minocycline/saline variables, F(1,24)=0.88, P=0.36. 
Bonferonni’s post-test revealed the IL-1β level was significant higher in the ipsilateral 
side (lesion) than in the contralateral side (non- lesion) in the control group ( p<0.05 
white), but not significantly difference between ipsilateral and contralateral side in the 
minocycline-treated group. The data are shown as mean ± SEM (n=7). 
 
5.2.3 Side Effects of Minocycline Treatment on Adult Rats 
 There was no mortality in either control or  minocycline-treated groups. The 
PVD II model caused a small (average of 6.7% ±0.2%) body weight loss at day 1 
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relative to body weight before injury. Afterward, the weight stopped dropping and 
gradually increased after 3 days, with an average gain of 3% by day 6. On day 1, the 
body weight loss (control 6.7% ± 0.2% vs minocycline 6.1% ± 0.5) between the two 
groups was similar. However, on day 3, when the control animals stopped losing weight, 
the body weights of the minocycline-treated animals kept declining and reached the 
maximum loss on day 6 (Fig 5-8). In the present study, minocycline treatment (45 mg/kg 
i.p. twice a day for the first day; 22.5 mg/kg for the subsequent 5 days) prevented the 
body weight gain that occurred after cortical lesioning between day 3 and 6 (P<0.05, 
Student t test).  Yellow-colored deposits have been observed on the surface of the liver, 
and/or on the intestines in some of the minocycline treated animals, varying among 
animals as judged by visual observation. These yellow deposits in the peritoneal cavity 
might be an indication of incomplete drug absorption as minocycline is a yellow powder 
and has poor water solubility. A similar observation has been reported in p ublications  
(Fagan et al., 2004b; Szymanska et al., 2006) that also used i.p. administration.  
 
                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7. Effects of minocycline treatment on body weight following PVD I I , 
represented as a percentage of pre-surgery weight. All rats lose weight on day 1 and day 
2 as a consequence of the PVD II. Minocycline treatment impeded the weight gain in the 
Day 1 Day 2 Day 3 Day 6
*
*
Pe
rc
en
ta
ge
 (%
) o
f P
re
-P
V
D
 II
 W
ei
gh
t
Days post PVD II
110
105
100
95
90
85
Day 0
Control
Minocycline
 72 
following days and reached a significant difference between day 3 and day 6. (*P<0.05). 
All the values in this graph are reported as the mean ± SEM.  
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5.3 Discussion 
In the present study, minocycline treatment showed no effect on the lesion 
volume. Therefore one has to conclude that there is no neuroprotective effect in this 
experimental irreversible stroke model. The untreated stroke lesion in control animals 
transforms normally into an extra-parenchymal fluid-filled cavity surrounded by the glia 
limitans as a new barrier. Minocycline treatment rescued this area as part of the 
parenchyma as the space was now occupied by reactive astrocytes. Although no neurons 
were rescued, this action may still result in beneficial effects as reactive astrocytes are a 
major source of trophic factors and other neuroprotectants (Pekny and Nilsson, 2005). 
The mechanism on which the prevention of cavitation is based could not be determined. 
Microglial activation and infiltration of leukocytes were unaffected by minocycline 
treatment as judged by the morphology and density of the GSAB4 positive cells, CD3 
and MPO positive cells. Although minocycline treatment showed a trend to reduce the 
expression of IL-1β, it failed to reach statistical significance.  
In regards to stroke-like conditions, minocycline has been mainly tested and 
shown to have neuroprotective effects on the MCAO model, the most common used 
focal ischemic animal model because of its clinical relevance (Yrjanheikki et al., 1998; 
Yrjanheikki et al., 1999; Xu et al., 2004; Koistinaho et al., 2005). Ischemic injury in the 
brain results in neuronal cell death, with characteristics of both necrosis and apoptosis 
(Lipton, 1999). Apoptosis, which is temporally and spatially different from necrosis in 
the infarct core, occurs mainly in the surrounding penumbra region (Mergenthaler et al., 
2004). Apoptosis is one of the direct targets of minocycline action (Domercq and 
Matute, 2004) and minocycline acts at the mitochondrial level to reduce the apoptosis of 
neurons and oligodendrocytes in various neurodegenerative disease models (Lee et al., 
2003a; Stirling et al., 2004; Zhu et al., 2002). The class II pial vessel disruption induces 
a small cortical  lesion, which mimics irreversible focal ischemia (Wang and Walz, 
2003). Compared to MCAO, it does not create a sizable penumbra of sub- lethal injury in 
the cortex and striatum (Gotts and Chesselet, 2005), thus fewer neurons are subjected to 
delayed death, and subsequently fewer neurons are potential targets for treatment (Muir 
and Grosset, 1999).  
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Another cause for the lack of effect on lesion volume by minocycline treatment 
could be the time point of the start of treatment. In the present study, the drug was 
delivered 1 hour post injury. Indeed, in a study using the permanent MCAO model, it 
has been shown that if minocycline treatment was initiated before lesioning, the 
ischemic infarct was dramatically reduced while no effect was observed when the 
treatment started 2 hours after the onset of the permanent MCAO (Koistinaho et al., 
2005).  In another study of a transient MCAO model on rat pups, minocycline 
treatment starting 2 hours after MCA occlusion only reduced the brain injury at 24 hours 
but not 7 days after lesioning. These authors, too, failed to find a minocycline-induced 
reduction of microglial activation or expression of local proinflammatory mediators such 
as IL-1β, IL-18, MCP-1 and CINC-1 (Fox et al., 2005). Minocycline did not inhibit 
microglia activation in the facial nucleus following crush injury either (Fendrick et al., 
2005).    
In the present study, treatment was delayed by 1 hour as this is a more realistic 
scenario for a clinical situation compared to pretreatment or simultaneous treatment with 
the time of lesioning. Another factor could be that intraperitoneal delivery of 
minocycline may take up to 4 hours to peak in the systemic circulation (Fagan et al., 
2004b). Consistent with their findings (Fagan et al., 2004b), an accumulation of the drug 
in the liver and intestine was also noted in some of the minocycline-treated animals, 
which may be associated with a delayed, incomplete and inconsistent absorption of the 
drug into the bloodstream. Such delays in reaching effective concentrations might be 
problematic because they may miss the therapeutic window, which is extremely 
important in acute CNS injury. The minocycline administration protocol used in this 
study was the same as the one used by Yrjanheikki et al. (1999) in the MCAO model, in 
which minocycline was successful in rescuing neurons. However, differences in the 
stroke models, regional brain areas, experimental species, strains and other parameters 
may require different dosages and treatment protocols in order to produce significant 
neuroprotective effects (Tsuji et al., 2004).  Intravenous injection of minocycline has 
been shown to be a more consistent and prompt delivery route (Fagan et al., 2004b). 
Therefore, it might be a more effective treatment following PVD I I , if acute 
neuroprotection is required. 
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However, despite a lack of effect on the stroke volume by day 6, it was found 
that minocycline abolished the substantial progressive cavitation that develops in more 
than 80% of the lesioned animals between day 14 and 21 (Wang and Walz, 2003).   The 
cavity was occupied in minocycline-treated rats by reactive, GFAP+ astrocytes. In 
addition, the glia limitans, which surrounds the cavity in control animals, was absent in 
these treated rats. Thus an important effect of minocycline treatment during the first six 
days after injury was that the loss of brain parenchyma, which appeared quite later, was 
prevented. Such an effect is new and has not been reported before. Given the importance 
of lacunar infarctions in human stroke pathology, this finding has relevancy in human 
treatment with minocycline. In addition, this effect could have important ramifications 
as the space was now populated by reactive astrocytes as part of the parenchyma. There 
was no apparent barrier separating these reactive astrocytes from adjacent surviving 
tissue. As these cells are known to produce neurotrophic factors, they could therefore 
help salvage neuronal survival, migration and axonal regeneration in adjacent areas.  
Progressive cavitation is closely related to the inflammatory response and is 
based on activation of microglia / macrophages and migration of reactive astrocytes out 
of the affected area (Fitch et al., 1999). This leads to abandonment by astrocytes leaving 
this area more vulnerable to inflammatory damage. Therefore it may not come as a 
surprise that this process is a natural target for minocycline. In the PVD II model, it was 
found that shortly after injury, PMNs were recruited and infiltrated the  lesion area, 
followed by delayed infiltration of T cells and activated microglia/macrophages (both 
from hematogenous origin and brain microglia) in the ischemic area and boundary zone. 
Astrocytes abandon the lesion within the first few days, but at the border they become 
reactive and divide. Six days after lesioning, an astrocytic boundary, known as glia 
limitans is formed, surrounding the lesion. By day 21 the lesion site is transformed into a 
fluid- filled cavity (Wang and Walz, 2003; Wang et al., 2004).  
In the present stroke model, minocycline treatment did not change any of the 
patterns of these cell types in the first six days. However, it prevented the formation of 
the cavity by filling up the space with reactive astrocytes between day 6 and 21.  It 
should be pointed out that minocycline treatment was stopped at day 6, when there was 
not yet a cavity. Reactive astrocytes most likely migrated back into the lesioned area, 
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and this migration prevented the formation of a fluid-filled cyst. It is usually persistent 
macrophage / microglia activation that is responsible for the outward migration of 
astrocytes (Fitch et al., 1999). Although in this study no direct evidence was found for 
reduced inflammation after minocycline treatment, it seems most likely that minocycline 
is preventing cavitation through its anti- inflammatory effect on microglia early in the 
first six days. Activated microglia/macrophages not only act as scavengers removing 
tissue debris, but also release numerous agents that are toxic to CNS cells, including 
inflammatory cytokines and glutamate, which aggravate secondary tissue injury and 
modulate the astrocyte response by releasing inflammatory cytokines, chemoattractants 
such as osteopontin (Wang et al., 1998a) and  MMPs (Planas et al., 2002). Among 
these inflammatory cytokines, IL-1β plays an important role in the signaling between 
microglia and reactive astrocytes (Giulian et al., 1988; Herx and Yong, 2001).  
An alterative explanation is that this repopulation was not caused by changes in 
diffusible microglia-astrocyte signals, but by changes in matrix molecules. Fitch et al. 
(1999) found that early in the progressive cavitation process, when the lesion is 
abandoned by astrocytes, but still filled with a high density of microglia / macrophages, 
there are increased levels of chondroitin sulfate proteoglycans (CSPGs), which prevent 
repopulation of the cavity by astrocytes. Thus, it may well be that minocycline in the 
first six days does not change the quantity of microglia activation but specifically 
down-regulates signals that prevent astrocyte repopulation, one of which might be 
CSPG.  
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6. METHODOLOGY DEVELOPMENT: I N  V I V O  
LABELING OF SVZ CELLS IN ADULT RATS 
6.1 Introduction 
It is now well accepted that neurogenesis in the adult rodent brain is retained 
within two restricted regions: the SVZ of the lateral ventricle and the DG of the 
hippocampus. SVZ multipotent progenitors give rise to neuroblasts that migrate to the 
OB via a restricted pathway, the rostral migratory stream. Upon reaching the 
subependymal zone, which is located in the middle of the OB, the majority of 
neuroblasts migrate to the granule cell layer while a small fraction of neuroblasts reach 
the glomerular layer, which is the most superficial layer in the OB, and then differentiate 
into interneurons in each region (Alvarez-Buylla and Lim, 2004).  
In response to ischemic injury in the adult brain, the appearance of new neurons 
has been observed in normally non-neurogenic regions, such as the neocortex, striatum 
and hippocampus, by several groups (reviewed in section 1.3.2). The appearance of 
these new neurons can be due to two mechanisms: 1) local parenchymal precursors 
might activate and differentiate into new neurons after injury; 2) precursors from 
normally neurogenic regions, such as the SVZ, might migrate towards the injured 
parenchyma in response to the ischemic stimulus. Recent studies have suggested that 
precursors from the SVZ might be the primary source of such newborn neurons in the 
adult (reviewed in section 1.3.2).   
Do SVZ-derived progenitors serve as an endogenous source for replacement 
associated with brain injury induced by PVD II? To address this issue, one needs a 
reliable method for labeling large numbers of SVZ precursor cells, thus making it 
possible to track their migration and differentiation. Several methods have been used to 
trace SVZ-derived progenitors during the migration process or after differentiation, such 
as the use of BrdU, fluorescence dyes and retroviral vectors 
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(Doetsch and Alvarez-Buylla, 1996; De Marchis et al., 2001; Parent et al., 2002; 
Petreanu and Alvarez-Buylla, 2002; Winner et al., 2002; Saghatelyan et al., 2003).  
BrdU, a thymidine analog, is administered intraperitoneally and is incorporated 
into newly synthesized DNA. An antibody directed against BrdU allows the 
identification of cells that have already incorporated BrdU, thus providing a marker for 
all cells that had DNA synthesis in the presence of BrdU (Taupin, 2006b). This will 
include all the dividing cells along the SVZ-RMS-OB axis. Retroviruses are suitable for 
identification of mitotic cells because viral integration only occurs when cells undergo 
complete cell division. RVs normally carry a reporter gene, whose expression requires 
viral integration into the host genome, and allows direct visualization and analysis of the 
transfected cells and their progeny. When such a vector is stereotaxically injected into 
the SVZ, dividing cells such as neural progenitors in this area would be infected. 
However, it seems the labeling efficiency is lower than with BrdU (Sohur et al., 2006). 
Lipophilic tracers, such as DiI or cell tracker green, can passively diffuse in between the 
lipid membrane bilayer of cells, therefore yielding excellent labeling of all neuronal 
processes. Thus, fluorescent tracers have also been used to labeling SVZ cells with the 
aid of stereotaxic injection (De Marchis et al., 2001).  
The aim of the following experimental section was to develop a reliable and 
reproducible method for in vivo labeling of large numbers of SVZ cells, thus making it 
possible to track their migration and differentiation. In the following study, three 
methods were compared: BrdU loading, retrovirus injection and fluorescent tracer 
injection, to label and trace SVZ-derived progenitors in the normal and injured rat brain. 
6.2 Results 
6.2.1 BrdU-Labeled Cells in the Normal and PVD II Rat Brains 
Three days after intraperitoneal BrdU injection (for protocol see Materials and 
Methods), the majority of BrdU-labeled cells in normal adult rats were located in the 
SVZ, the RMS and the hippocampus, all a reas where neurogenesis persists into 
adulthood. In addition, a few BrdU-labeled cells were scattered throughout the corpus 
callosum and the parenchyma of the neocortex. This probably indicates glial 
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proliferation, which occurs at a slow rate in these areas. In rats subjected to PVD II, 
there was a substantial number of BrdU+ cells in addition to those observed in the 
normal brain: these were inside and around the cortical ischemic lesion two or three days 
after PVD II (Fig 6-1). 
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Figure 6-1. Distribution of BrdU+ cells two days after PVD II. A: Parasagittal section, 
including the whole RMS, demonstrates BrdU labeling throughout almost the entire 
length of the RMS (densely stained red line). B: The parasagittal section includes the 
lesion from the same animal. A substantial number of BrdU+ cells were observed in the 
PVD II lesion. Although the majority of BrdU-labeled cells were located in the SVZ of 
LV, the RMS and the hippocampus, a few BrdU+ cells were also scattered throughout 
the CC and the parenchyma of the neocortex. Red dots are the BrdU+ cells. Scale bar: 
200 µm. RMS: rostral migratory stream; LV: lateral ventricle; CC: corpus callosum.  
6.2.2 Retrovirus Labeled Cells in the Normal and PVD II Rat Brains  
RVs will only be taken up by mitotic cells (Craig et al., 1999; Hu and Pathak, 
2000). A replication-deficient RV carrying the Lac-Z gene, which produces the marker 
enzyme β-galactosidase, was utilized to label proliferating neuronal progenitors in the 
SVZ (Craig et al., 1999).  Four or 6 days after intraventricular injection of the RVs, 
only a few labeled migrating cells were seen along the SVZ-RMS-OB pathway (Fig. 
6-2). Surprisingly, there were very few labeled cells in ependymal and subependymal 
cell layers. Instead, many choroid plexus cells were labeled by β-galactosidase. In 
addition, scattered β-galactosidase labeled cells were observed elsewhere in the rest of 
the brain. The density of labeled cells in different brain areas are as follows: choroid 
plexus > olfactory bulb > striatum > cortex (Fig. 6-2). Except in the choroid plexus, 
most of the labeled cells had a macrophage- like morphology and were associated with 
blood vessels. In the PVD II animals, some labeled cells were observed within the 
lesion, exhibiting a morphological appearance similar to macrophages. 
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Figure 6-2. Distribution of β-galactosidase positive cells (blue cells) six days after 
intraventricular injection of RVs, in the RMS (A), choroid plexus (B), cortex (C), 
striatum (D), OB (E, F). Only a  f ew  labeled migrating cells were seen along the 
SVZ-RMS-OB pathway. The labeled cells can be seen elsewhere in the brain and the 
order of their density is: choroid plexus (B) > olfactory bulb (E, F) > striatum (D) > 
neocortex (C). Labeled cells are very often found associated with blood vessels. Scale 
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bar: 100 µm. BV: blood vessel; RMS: rostral migratory stream; SVZ: subventricular 
zone.  
 
 
6.2.3 DiI-Labeled Cells in the Normal and PVD II Rat Brains  
Similarly, injection of DiI into the adult brain lateral ventricle resulted in strong 
labeling of cells in the ependymal layer throughout the ventricular system including the 
contralateral lateral ventricle. This suggests that injection of DiI into the lateral ventricle 
results in the movement of DiI throughout the CSF. However, it did not result in 
DiI- labeled migrating cells in the RMS or olfactory bulb. Taking into consideration the 
architecture of the SVZ, SVZ cells have little direct contact with the lateral ventricle 
since it is separated from the lateral ventricle by the ependymal cell layer. Thus, to target 
SVZ cells, the injection site should be aimed directly at the subventricular area of the 
lateral ventricle. 
In order to position the tip of the needle in the SVZa, three coordinate references 
to either the bregma skull or pial surface were tested (Table 6-1). Stereotaxic injection of 
DiI into SVZa resulted in a strong labeling of the lateral ventricle, which suggests that 
the released DiI was not restricted to the SVZa, but could diffuse into different cell 
layers of the lateral ventricle. However, in contrast to the injection into the lateral 
ventricle, strong DiI labeling of the RMS and the core of the OB were observed in all the 
SVZa injected animals. The higher-magnified view shows that the DiI-labeled migrating 
cells are organized as chains (Fig 6-3). Although DiI injection into the SVZa resulted in 
very strong labeling of the RMS and the core of the OB, a major issue encountered in 
this study was the lack of a difference in the migratory distance of labeled cells between 
day 5 and day 11 post- injection animals (Table 6-1). No DiI- labeled cells were observed 
in the granule cell layer of the OB even 11 days after the injection, which contradicts the 
findings in the literature. It has been suggested that the neuroblast migration from the 
SVZ to the OB will take 2 to 9 days (Petreanu and Alvarez-Buylla, 2002; Geraerts et al., 
2006).  
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Table 6-1. Cell labeling after DiI microinjection into the SVZa at different stereotaxic 
coordinates after different survival times. 
 
AP ML D RMS OB 
core
GCL
0 1.4 4.8 5 1 +++ +++ -
0 1.4 4.6 11 1 +++ +++ -
0 1.5 3.3* 11 1 +++ +++ -
0.5 1.4 4.8 5 1 +++ +++ -
Coordinate (SVZa) Survival days
n
DiI labeled cells
 
 
Stereotaxic coordinates are with reference to the bregma (mm).  AP, anteroposterior; ML, medial lateral; D, depth 
from the skull surface; *represents the depth from the dura matter.  Sections were visually scored for the density of 
DiI labeling in the RMS and OB; +++, dense labeling, ++ moderate labeling, + weak labeling, - no labeling. RMS: 
rostral migratory stream; OB: olfactory bulb; GCL: granule cell layer; SVZa: anterior of subventricular zone. 
 
 
 
 
 
 
 
 
 
Figure 6-3. DiI labeling after stereotaxic injection into the SVZa. Stereotaxic injection 
of DiI into the SVZa resulted in strong DiI labeling of the RMS and the wall of the 
ventricular system (A) in all injected animals. B: The higher-magnified view of RMS 
(boxed region in A). The nuclei were stained with Hoechst 33243. In contrast, DiI 
injection into the LV results in heavy labeling of the ependymal layer throughout the 
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ventricular system only, but very weak or no labeling of the RMS. Scale bar: 200 µm 
(A); 100 µm (B). LV: lateral ventricle; RMS: rostral migratory stream.  
6.2.4 Migration of CFSE-Labeled SVZ Cells in Normal Rats 
CFSE is a lipophilic molecule. However, unlike DiI, it is colourless and 
nonfluorescent until it is transported into cells, where its acetate groups are cleaved by 
intracellular esterases. To investigate the suitability of CFSE as a label for the 
SVZ-derived progenitors, 200 nl of 10 mM CFSE were injected into the SVZa and the 
animals were sacrificed at different time points (1, 3, 5, 7 and 14 days). Since CFSE was 
injected into the brain tissue (SVZa) instead of ventricles, the injection volume was 
reduced to 200 nl rather than µl volumes, and the injection speed was limited to 0.1 
µl/min with the aid of a microinjector in order to minimize the tissue damage induced by 
the in vivo injection. After injection and sacrifice, parasagittal sections were cut in the 
cryostat.  Preliminary experiments were carried out to test the different concentrations 
(10 µ M, 100 µ M, 1 µ M, 10 mM) for CFSE, with 10 mM resulting in the strongest cell 
labeling as indicated by visual observation.  
One day after CFSE injection, labeled cells were found mainly in the SVZ and 
RMS, but not in the core of the OB. Three days later, labeled cells were detected not 
only in the RMS, but also in the OB, which is in accordance with previously described 
reports, in which neuroblast migration from the SVZ to the OB occurs within 2 to 9 days 
(Luskin, 1993; Petreanu and Alvarez-Buylla, 2002). CFSE labeled cells in the RMS 
showed the typical morphology of migrating neuroblasts, that is an elongated cell body 
and a leading process usually pointing toward the OB (Fig 6-4).  By days 5-7, CFSE 
labeled cells were observed along the RMS and in the core of the OB. From 7 days on, 
labeled cells started to appear in the GCL of the OB. By days 10-14, more labeled cells 
were observed in the GCL and some labeled cells were also seen in the more superficial 
layers of the OB, such as the glomerular layer. At day 14, the fluorescence intensity was 
decreased and the fluorescence distribution became uneven, but the labeling was still 
detectable. In addition, cells in the SVZ were always strongly labeled at any time period 
examined.  
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Both ipsilateral SVZ cells and ependymal cells were labeled with CFSE, while 
contralateral ependymal cells were rarely labeled and no CFSE-labeled cells were found 
on the pial surface. These findings suggest that with this injection method, CFSE was 
not transported within the bulk flow of cerebrospinal fluid and did not label the 
contralateral lateral ventricle as shown by some authors (Ramaswamy et al., 2005). 
Outside the SVZ-RMS-OB axis, some CFSE-labeled cells were observed in the striatum 
at all time points. Other than these cells in the striatum, very few CFSE-labeled cells 
were observed outside of the SVZ-RMS-OB axis.  T o  determine the identity of the 
labeled cells, immunostaining was performed: CFSE-labeled cells in the SVZ and the 
RMS were DCX+. A number of DCX+ cells were labeled with CFSE (Fig 6-5). This 
indicates that a considerable number of migrating neuroblasts was labeled by the CFSE 
injection into the SVZa.    
In conclusion, CFSE labels and stays in SVZ cells through several generations 
and it can be detected in SVZ progeny for at least 14 days. By injecting CFSE into the 
anterior of the SVZ, SVZ-derived progenitors and their progeny could be traced. 
Therefore, this method is a useful tool to study SVZ-derived cell migration and 
differentiation. 
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Figure 6-4. Distribution of CFSE-labeled cells in the adult rat brain seven days after 
CFSE injection into SVZa. A: Schematic drawing with the injection site on the 
parasagittal brain section. B: Enlargement of the orange box in A, giving an overview of 
CFSE-labeled cells. C, CFSE-labeled cells in the RMS, enlarged view of the right square 
outlined area in B. D: CFSE labeled cells in the GCL of OB, enlarged view of the left 
square outlined area in B. Scale bar: 200 µm. RMS: rostral migratory stream; OB: 
olfactory bulb; GCL: granule cell layer; Ctx: cortex.  
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Figure 6-5. Typical appearance of CFSE-labeled cells in the RMS in the parasagittal 
sections, 3 days after CFSE injection into the SVZa. A: GFAP immunostaining shows 
that CFSE-labeled cells in the RMS do not express GFAP. These CFSE-labeled cells 
migrate through a tube- like structure, which is formed by cells expressing GFAP. B: 
DCX immunostaining shows that all CFSE-labeled cells also express DCX in the RMS. 
C: Same section viewed with the aid of a confocal microscope, which confirmed the 
colocalization of DCX and CFSE (white arrows). Scale bar: 50µm. 
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6.3 Discussion 
To date, in vivo labeling of SVZ cells of adult brain has been achieved by BrdU 
administration, retrovirus or fluorescent tracer injection. In this study, I compared these 
different methods, assessed their effectiveness and conclude that the CFSE injection 
method into the SVZa outperforms the other two methods, using reproducibility and 
efficiency of the labeling of adult rodent SVZ precursor cells as criteria.    
I have shown that SVZ-derived neuronal progenitors can be labeled by BrdU. 
BrdU has been the most commonly used method in the studies of neurogenesis. 
However it has certain disadvantages. It has been reported that high concentrations of 
BrdU are toxic and that repeated administration is stressful for animals (Rakic, 2002). 
BrdU only labels the nucleus, therefore the images do not highlight the cytoplasm, 
dendrites and axons of the labeled cells. Moreover, incorporation of BrdU depends on 
various factors such as blood flow and vascular permeability, which are affected by the 
lesions. In order to avoid labeling the proliferating astrocytes, microglia and infiltrated 
inflammatory cells that are activated by ischemic injury, BrdU was loaded before the 
induction of the PVD II. Still, substantial numbers of BrdU-labeled cells were observed 
in the ischemic lesion 3 days after injury, which suggests that cells of hematopoietic 
origin were labeled and that they infiltrated the lesion. Double staining for a neuronal 
progenitor cell marker (using DCX o r  ß I I I -tubulin) in combination with 
immunohistochemistry for BrdU would be able to confirm the neuronal phenotypes of 
the newly generated (BrdU+) cells. However, I would still not be able to conclude that 
these cells originated from the SVZ, because BrdU was administrated systemically and 
therefore it potentially labels all proliferating cells including cells that divide in situ in 
the parenchyma, such as oligodendrocyte precursor cells (OPCs) as well as cells of 
hematopoietic origin that infiltrate after injury. Stereotaxic injection of BrdU into the 
SVZa might overcome the above-mentioned problems and therefore provide a useful 
tool to label SVZ precursor cells (Ohab et al., 2006).  
Ventricular injection of the retrovirus resulted in sparse labeling along the 
SVZ-RMS-OB pathway. A possible explanation is that as the ependymal layers form a 
physical barrier with the underlying SVZ, only a very limited number of type B cells in 
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the SVZ are in contact with the ventricular lumen (Doetsch et al., 1997; Doetsch et al., 
1999). Subsequent experiments with DiI injection into the lateral ventricle resulted only 
in heavily labeled ependymal cells throughout the ventricular system, but very weak or 
no labeling of cells in the RMS. The results therefore confirm this assumption. Indeed, a 
study by Rogelius et al. (2005) showed that injection of RV into the lateral ventricle of 
adult rats resulted in the labeling of only a few cells along the SVZ-RMS-OB pathway, 
whereas injection into the SVZ dramatically improved the labeling efficiency. Consiglio 
et al. (2004) reported as well that injection of a lentiviral vector into the SVZa but not 
into the lateral ventricle resulted in labeling of OB neurons. Labeled SVZ cells ha ve 
been reported using both intraventricular injection (Morshead et al., 1998; Craig et al., 
1999) and SVZ injection (Petreanu and Alvarez-Buylla, 2002; Yamada et al., 2004) of 
RV. However, it is difficult to compare the results of different investigators as 
transfection efficiency depends largely on the virus concentration, the injected volume 
of the virus and the choice of promoter (Vercelli et al., 2000). In the present study, the 
injection of RVs into the lateral ventricle failed to label even ependymal cells, which are 
slowly dividing cells (Doetsch et al., 1999). Instead, RVs preferentially labeled choroid 
plexus cells. The reason that the delivery of retrovirus into the lateral ventricle resulted 
in a selective transfection of choroid plexus cells but not ependymal cells is not entirely 
clear. It may be due to the RV preferentially labeling fast dividing cells (Rogelius et al., 
2005). Surprisingly, scattered β-galactosidase labeled cells were observed everywhere in 
the brain parenchyma. Most of the labeled cells had a macrophage-like morphology and 
were associated with both small and large blood vessels. Due to their morphology, close 
association with the vasculature and their position on the abluminal surface of the 
vessels, I propose these cells are pericytes or perivascular cells (Thomas, 1999; Allt and 
Lawrenson, 2001; Betsholtz et al., 2005). Hematopoietic stem cells (HSC) derived from 
bone marrow have been shown to differentiate into both parenchymal microglia and 
perivascular cells in the brain and the numbers of these cells increase after cerebral 
ischemia (Hess et al., 2004; Kokovay et al., 2006). In this study, the RVs might have 
been transported with the CSF bulk flow, absorbed at the venous sinuses, making their 
way into the blood circulation, where RVs labeled the bone marrow-derived cells, such 
as HSC. However, no labeled  ce l l s  having the highly ramified morphological 
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characteristic of parenchymal microglia were observed in this case. This might be due to 
the different differentiating time of the lineage derived from bone marrow. In a study 
that used transplanted high level hematopoietic reconstitution from a single enhanced 
green fluorescent protein (EGFP) stem cell into lethally irradiated recipient mice, there 
were few BM-derived (EGFP+) microglia cell s  in  the brain parenchyma 2 months 
post-transplantation. However, 4 months later, these cells were abundant in all mice that 
survived for 4 months or more post-transplantation, whereas BM-derived (EGFP+) 
pericytes were observed in the brain at both time points (Hess et al., 2004). This 
suggests that a different period of time may be needed for these HSC-derived cells to 
engraft as parenchymal microglia and pericytes. However, a further investigation of the 
nature of these cells is beyond the scope of this project.  
Injection of DiI into the anterior of the SVZ resulted in very strong labeling of 
the RMS and the core of the OB 5 to 11 days after injection. Because of the extremely 
strong fluorescence in the SVZ and RMS, both with very high cell densities of labeled 
cells, it is hard to distinguish the individually labeled cells. Moreover, no labeled cells in 
the GCL of the OB were observed, even 11 days after the injection. Therefore, it is 
difficult to distinguish if the extremely strong DiI fluorescence of the RMS and core of 
the OB is the result of a large number of strongly DiI-labeled cells diffusing from the 
injection site or of leakage from previously labeled cells due to cell membrane damage. 
Cryostat sectioning was used to process tissue sections in this part of the study. Cryostat 
sectioning is known to cause damage to cell membranes. If this occurs, it could cause 
DiI leakage out of labeled cells (Vercelli et al., 2000). As DiI is a lipophilic 
carbocyanine dye, any permeabilizing reagents, detergents, or high concentrations of 
organic solvents have the potential to result in degradation of DiI labeling and cause the 
leakage of some DiI into the extracellular space. This would make it difficult to perform 
immunohistochemistry experiments, as these require disruption of the phospholipid 
bilayer. As well, the usage of antifade mounting media that contains glycerol, (such as 
citifluor) will extract membrane-bound DiI (Terasaki and Jaffe, 1991; Hayaran and 
Bijlani, 1992; Vercelli et al., 2000).  I  therefore think that the fading of the dye and 
fluorescent labeling in the sections is a serious enough issue to interfere with the 
reliability of this labeling method. I n the present experiments immunofluorescent 
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staining will always have to be applied in order to characterize the phenotype of the DiI 
labeled cells. Double staining is also needed for quantification and co-localization 
procedures. It therefore is unavoidable. Taking into consideration all these limitations of 
DiI, the use of DiI in vivo labeling of SVZ cells for this study was not implemented. 
CFSE was chosen for this study because it offers several advantages over DiI. Its 
succinimidyl ester group reacts covalently with the free amino groups of intracellular 
macromolecules, which enhance its retention time within cells and therefore its ability to 
be retained intracellularly throughout the aldehyde fixation and immunostaining 
procedures. Another advantage of CFSE is that it is colorless until it is transported into 
cells, where its acetate groups are cleaved by intracellular esterases and it is only then 
that it becomes a highly fluorescent molecule. Therefore, excess unconjugated reagent 
will passively diffuse through the extracellular space and will be diluted, but it will not 
be fluorescent. Due to these properties, CFSE-labeled lymphocytes have been 
successfully tracked in vivo up to 8 weeks after injection into mice (Weston and Parish, 
1990). CFSE has predominantly been used in lymphocyte proliferation and migration 
studies and it has also been used to track transplanted Schwann cells (Li et al., 2003) and 
neuronal cells in vivo (Paramore et al., 1992). It has also been shown that the fluorescent 
signal diffuses evenly throughout the cytoplasm of the labeled cells and is evenly 
divided between daughter cells with high fidelity and without leakage (Li et al., 2003).  
In this study, the effectiveness of an injection of CFSE into the SVZa of adult 
rats to label migrating SVZ cells was assessed. The time of appearance and the 
phenotype of SVZ cells in the RMS and OB were consistent with previous studies using 
different approaches (Petreanu and Alvarez-Buylla, 2002). The time required for newly 
generated SVZ neuroblasts to reach the OB is 2 to 9 days (Luskin, 1993; Petreanu and 
Alvarez-Buylla, 2002). In the present study, within that time frame, most labeled cells 
were located in the OB, distributed in different layers. Unlike RV-based labeling that 
will only label dividing cells, preferentially fast dividing cells, CFSE will label all SVZ 
cells. Although no quantification was done, it seems the number of labeled cells in the 
RMS decreased over time, as the labeled cells were found to migrate further into the OB. 
However, cells in the SVZ were always well- labeled. This disappearance of 
CFSE-labeled cells from the RMS indicates that the primary cell types labeled by the 
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CFSE injection into the SVZa in this study are the fast dividing precursors (type C) and 
neuroblasts (type A). Very few stem cells (type B) were labeled. An alternative 
explanation is that the neural stem cells (type B) were labeled and the fluorescence was 
diluted out when the cells differentiated into neuroblasts and immature neurons due to 
the frequent cell division. This also highlights some of the limitations of using vital 
fluorescent dyes to mark the ontogeny of cells in vivo.  
Compared with DiI, CFSE is able to be retained throughout fixation and 
permeabilization procedures. In this study, it has been demonstrated that cells within the 
SVZ can be labeled and followed over 14 days after injection of CFSE into the SVZa.  
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7. APPEARANCE OF MIGRATING NEUROBLASTS IN 
THE ISCHEMIC PENUMBRA OF THE PVD II-INDUCED 
LESION 
7.1 Introduction 
Adult neurogenesis is a phenomenon that has received a lot of attention in the 
last decade. As reviewed in the Introduction (section 1.3.2), although adult neurogenesis 
in the mammalian CNS is a robust and reproducible occurrence, four qualifications have 
to be considered. 1) Adult neurogenesis is species-dependent with what appears to be a 
gradual restriction during evolution (Bhardwaj et al. 2006). 2) While there is no doubt 
that this phenomenon occurs in the subventricular zone, olfactory bulb and dentate gyrus 
of many species, especially rodents, its occurrence in other brain areas is controversial 
(Bhardwaj et al., 2006). 3) Adult neurogenesis can be enhanced and induced by factors 
in the environment like behavior patterns associated with learning, as well as by injury 
(e.g. ischemia, hemorrhage, etc.) or drug treatment (Lindsey and Tropepe 2006). 4) It 
has also to be kept in mind that many newly generated neurons may have a transient 
appearance and may never turn into mature cells, much less into full- fledged participants 
of neural circuits (Lledo et al. 2006). 
Most of the studies on post-stroke neurogenesis have used stroke models 
involving large vessel occlusion, resulting in massive lesions, such as MCAO. The PVD 
II model is a modified cortical devascularizing model that is induced by the disruption of 
only the medium sized pial vessels on a 5 mm diameter cortical surface. This creates a 
small cone-shaped cortical lesion, restricted mainly to the frontal cortex, involving 
mostly the primary motor cortex and sometimes the hindlimb sensorimotor cortex as 
well. The tip never reaches deep enough to touch the corpus callosum (Wang and Walz, 
2003). After two weeks, cavitation develops at the site of the lesion.  
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This stroke model therefore has features resembling the lacunar infarctions 
observed in humans as a result of small vessel occlusion and silent strokes. Reactive 
astrocytes surround the lesion, and those in the space between the base of the lesion and 
the corpus callosum are highly reactive, expressing a high density of vimentin (Wang et 
al., 2004). This area is strategically situated along a hypothetical pathway, SVZ – RMS - 
corpus callosum – lesion. One function of these vimentin+ reactive astrocytes could be 
to serve as a guiderail for the migration of neuroblasts or other newly created precursor 
cells. Indeed, it  was shown here  that DCX+ cells appear with the morphology of 
migrating neuroblasts. Although these DCX+ cells were seen both in the portion of the 
ischemic penumbra containing vimentin+ astrocytes and in the adjacent part of the 
corpus callosum, I w as not able to confirm that these cells arose from the SVZ/RMS 
pathway.   
7.2 Results 
7.2.1 No DCX+ Cells in the Neocortex of Control Rats   
Control rats include normal rats that had no surgery, and sham rats, which 
underwent the whole pial vessel disruption procedure except the disruption of the class 
II vessels. As expected, the strongest DCX immunoreactivity in normal and sham rats 
was found in the lateral and dorsal SVZ of the lateral ventricle, the RMS, the accessory 
olfactory bulb, and the dentate gyrus of the hippocampus (Fig. 7-1 A, F, G). DCX+ cells 
in the RMS assembled into chains and showed the characteristic morphology of 
migrating neurons: an ovoid cell body with a leading process (Fig. 7-1 B). Isolated or 
clusters of DCX+ cells were also seen in the corpus callosum, with their morphology 
resembling migrating neurons (Fig. 7-1 E), and in the striatum of these sham and normal 
rats (Fig 7-1 C, D). The characteristic morphology of DCX+ cells in the striatum 
appeared more like differentiated neurons with long branched processes (Fig. 7-1 D). 
Numerous DCX+ cells in the RMS were double-labeled with Ki67, which is a marker 
for dividing cells (Lu et al., 2005). The expression of Ki67 by the DCX+ cells indicates 
they are proliferating as they migrate along the SVZ/RMS as shown previously by 
Komitova et al. (2005). DCX immunostaining of parasagittal sections of both normal 
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and sham rats did not reveal any DCX+ cells in the neocortex. In addition, there were no 
DCX+ cells in the cortex of the contralateral hemisphere of rats that underwent PVD II 
at any time period investigated in this study. 
 
 
 
 
 
Figure 7-1.  Distribution of DCX+ cells in the normal adult rat brain. A: Overview of a 
parasagittal section shows intense immunostaining in the dorsal and anterior SVZ of the 
lateral ventricle, RMS and the accessory OB.  B, C: Higher magnified views of the 
rectangular crop areas in A. B, Enlarged view of the RMS. The Hoechst counterstained 
DCX+ neuroblasts are densely packed and chain-migrating in the RMS. C: Enlarged 
view of the striatum and striatal SVZ. Scattered DCX+ cells (arrows) in the vicinity of 
the SVZ. D: Morphology of typical DCX+ cells in the striatum. E: Morphology of the 
typical DCX+ cells in the CC.  F: DCX immunoreactivity in the DG of the 
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hippocampus. G: Higher magnified view of the rectangular crop area in G. Scale bar:  
400 µm (A); 200 µm(B, F), 100 µm (C, G); 20 µm(D,E). RMS: rostral migratory stream; 
OB: olfactory bulb; LV: lateral ventricle; Str: striatum. DG: dentate gyrus; CC: corpus 
callosum. 
 
 
7.2.2 DCX+ cells in the Neocortex and Corpus Callosum after the PVD 
II Lesion 
In the present study, adult rats were sacrificed 1 (n=5), 3 (n=3), 5 (n=5), 10 (n=5) 
and 14 (n=4) days after pial vessel disruption. Unlike what was seen in the normal and 
sham rats, DCX+ cells were located in the neocortex between the PVD II- induced lesion 
and the CC in 1 out of 5 rats of the day 1 post injury group, 2 out of 3 rats in the day 3 
post injury group, 2 out of 5 rats in the day 5 post injury group, 4 out of 5 rats in the day 
10 post injury group and 3 out of 4 rats in the day 14 post injury group. These DCX+ 
cells in the neocortex had a morphology resembling differentiated post migratory 
neurons with long branched processes (Fig. 7-2 C, D, E). A larger number of  DCX+ 
cells were observed in the corpus callosum of PVD II lesioned rats and  these cells 
were more likely to exhibit a migratory morphology with leading and trailing processes 
(Fig. 7-2 F). 
The number of DCX+ cells in the neocortex and corpus callosum underneath the 
PVD II lesion was quantified in all groups. The one-way ANOVA revealed a significant 
increase of the number of DCX+ cells in the corpus callosum on day 5, 10 and 14 as 
compared to the number in the normal rats (n=3) and day 1 post injury. The one-way 
ANOVA did not reveal a significant effect of the time post- infarct for the number of 
DCX+ cells in the neocortex (Fig 7-3). However, in contrast there were no DCX+ cells 
in the neocortex of normal rats (see above) and sham rats; the DCX+ cells only appeared 
in the neocortex after PVD II and were maintained till 14 days after PVD II lesion (Fig. 
7-3). By twenty-one days, the DCX+ cells were still present in the ischemic penumbra of 
the neocortex in 1 out of 3 animals. However, by 21 days post lesion, the numbers of 
DCX+ cells in both corpus callosum and neocortex appeared to decrease. 
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Figure 7-2. Distribution of DCX+ cells 14 days after PVD II. A: Schematic drawing of a 
representative parasagittal plane in an adult rat brain with the highest density of DCX+ 
cells. B: DCX+ cells were observed between the RMS and the lesion in both neocortex 
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and corpus callosum (CC).  The area, which is represented by this overview picture, is 
given in the orange box in the drawing in A. C, D, E, F: Higher magnification of the 
rectangular areas c, d, e, f in B. They represent white matter (f) and the neocortex 
surrounding the lesion (c, d, e). Inserted pictures are the enlarged view of DCX+ cell 
(white arrow) merged with nuclei labeling (Hoechst, blue). The DCX+ cells in the 
neocortex exhibit a morphology more like differentiated post-migratory neurons (arrows 
in C, D and E) and DCX+ cells underlying white matter exhibit a migratory morphology 
with leading and trailing processes (arrow in F). Scale bar: 200 µm (B), 100 µm (C, D, 
E, F). CC: corpus callosum. OB: olfactory bulb; LV: lateral ventricle; Str: Striatum; Hp: 
hippocampus. 
 
 
 
 
Figure 7-3. Quantification of DCX+ cells in the neocortex and corpus callosum 
underneath the lesion per 40 um-thick section at different time points after PVD II. The 
one-way ANOVA was applied to the data, with the data for the corpus callosum and 
neocortex being analyzed separately for statistical significance. Multiple post hoc 
comparisons were performed with Bonferonni’s multiple comparison post-test. The 
one-way ANOVA showed a significant main effect of the time post- infarct for the 
number of DCX+ cells in the corpus callosum, F(5, 19)=5.622, *P < 0.002). However, 
the main effect of the time post- infarct was nonsignificant for the number of DCX+ cells 
in the neocortex, F(5,19)=1.064, P=0.41). Bonferonni’s post-test revealed the number of 
DCX+ cells in the corpus callosum was significantly higher (*p<0.05) in the post-infarct 
Day5, Day10 and Day14 rats than in either Day1 or in normal animals.  
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7.2.3 Further Characterization of the DCX + Cells  
DCX, a microtubule-associated protein, is required for normal neuronal 
migration in the developing CNS and it is expressed in both radially and tangentially 
migrating neuroblasts. In contrast to the frequent colocalization of DCX and Ki67 in 
SVZ and RMS cells, the DCX+ cells underlying the lesion were not colabeled with Ki67, 
which suggests they were postmitotic (data not shown). Not a single DCX+ cell was 
observed that coexpressed markers of glia precursors or mature glia, NG-2, vimentin and 
GFAP. However, some of the DCX+ cells were immunoreactive for βIII-tubulin (Fig 
7-4), another marker of immature neurons, which further confirmed their neuronal 
lineage. Thus, the appearance of DCX can be taken as a sign of immature, migrating 
cells of the neuronal lineage.  
 
 
 
 
Figure 7-4. High-power confocal images showing a subset of DCX+ cells express 
βIII-tubulin. Cells double labeled (arrow) for DCX (green, A), βIII-tubulin (red, B), and 
overlap (orange, C) in the neocortex surrounding the lesion 5 days after PVD II. Scale 
bar: 20 µm.  
 
 
7.2.4 In Vivo Labeling of Migrating Neuroblasts in the Subventricular 
Zone in Control Rats 
The appearance of DCX+ cells in the neocortex is an indication that neuroblasts 
are trying to replace dead neurons. I hypothesize that these DCX+ neuroblasts were 
recruited in response to the ischemic injury from the SVZ and RMS into the neocortex 
 100 
near the lesion. In order to test this hypothesis, SVZ cells of adult rats were labeled by 
stereotaxic injection of CFSE into the SVZa. The temporal and spatial distribution of 
CFSE-labeled SVZ cells and the character of labeled cells in the sham rats (CFSE 
injection followed by sham PVD II procedure), are similar to the distribution in normal 
rats (for details of distribution and migration of CFSE-labeled cells see section 6.2.4).  
7.2.5 CFSE-Labeled Cells in PVD II Rats  
The fluorescent cell tracker CFSE was injected unilaterally into the SVZa before 
the induction of the cortical ischemic lesion by disrupting the class II pial vessels. Rats 
were sacrificed 1(n=6), 3 (n=6), 5 (n=7), 7 (n=5), 10 (n=6) and 14 (n=8) days after the 
surgery. The successful labeling of SVZ cells in each animal was confirmed by the 
strong labeling of CFSE labeled cells in the SVZ, in the RMS and in the OB (data not 
shown). Although many CFSE-labeled cells were observed in the RMS and in the OB, 
there were no CFSE-labeled cells observed in either the corpus callosum or the ischemic 
penumbra underlying the lesion.  
To test the possibility that neuroblasts born after the PVD II- induced injury were 
the ones preferentially being recruited to migrate towards the lesion, CFSE was injected 
into the SVZa 2, 3 and 5 days after PVD II and the animals were sacrificed 10 days (n=3) 
or 14 days (n=3) after making the lesion. There were still no CFSE-labeled cells located 
in either ischemic penumbra or the corpus callosum underneath the lesion. 
 
7.3 Discussion 
A cortical ischemic injury is induced by disrupting the pial vessel II on the 
sensorimotor cortex of adult Wistar rats. In response to this injury, DCX-expressing 
cells were present in the neocortex and corpus callosum underneath the lesion up to 14 
days after injury. In this study, DCX was used as the principal marker of the migrating 
neuroblasts and immature neurons (Francis et al., 1999; Nacher et al., 2001). DCX, a 
microtubule-associated phosphoprotein, is required for normal neuronal migration in the 
developing CNS and is expressed in the migrating neuroblasts in both developing and 
adult brain. In the adult brain, DCX expression is mainly retained within the two areas of 
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continuous neurogenesis. It has been suggested that DCX is a reliable and suitable 
marker for adult neurogenesis (Brown et al., 2003; Couillard-Despres et al., 2005) and it 
is transiently expressed in newly generated neurons (Ming and Song, 2005). 
Furthermore, these DCX+ cells displayed the typical morphology of migrating 
neuroblasts in the white matter and differentiated neurons in the neocortex (Nacher et al., 
2001; Brown et al., 2003) and they do not express markers of glia cells, such as GFAP 
and NG2, but another marker of immature neurons, βIII-tubulin. Therefore, based on 
both morphological and immunochemical characters, the appearance of DCX+ 
neuroblasts in the neocortex is an attempt of the brain to replace the dead neurons in 
response to ischemic injury. It is an indication of a repair process in the adult brain in 
response to the ischemic injury, although the numbers suggest the density of neuroblasts 
is at a low level.   
To date, post-stroke neurogenesis has been well studied, mostly in the massive 
ischemic injury model induced by occlusion of MCA, and accumulating evidence 
suggests that focal ischemic injury can induce neurogenesis in peri- infarct striatum 
(Arvidsson et al., 2002; Parent et al., 2002; Jin et al., 2003; Zhang et al., 2004; Nygren et 
al., 2006a; Thored et al., 2006; Yamashita et al., 2006) and/or neocortex (Gu et al., 2000; 
Jiang et al., 2001; Jin et al., 2003; Ohab et al., 2006). Within the first two weeks, 
newborn immature neurons as indicated by the expression of neuronal lineage cell 
markers such as DCX or βIII-tubulin were observed in tissue surrounding the infarct 
area (Arvidsson et al., 2002; Parent et al., 2002; Jin et al., 2003; Zhang et al., 2004; 
Nygren et al., 2006a; Yamashita et al., 2006).   A few weeks later, a portion of the 
newly generated cells expressed the markers for mature neurons, such as NeuN and 
region-specific mature neuronal markers, such as DARPP-42 and calbindin (Arvidsson 
et al., 2002; Parent et al., 2002; Yamashita et al., 2006). Interestingly, using different 
variations of the MCAO model, a model mimicking focal ischemia and inducing an 
excessive infarct in both neocortex and striatum, some studies found post-stroke 
neurogenesis in the injured cortex (Jiang et al., 2001; Jin et al., 2003). Other studies 
failed to detect cortical neurogenesis (Arvidsson et al., 2002; Parent et al., 2002; Zhang 
et al., 2004; Yamashita et al., 2006). However, all of these studies found moderate levels 
o f   post-stroke neurogenesis in the striatum. A recent study has shown substantial 
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cortical neurogenesis in the peri- infarct cortex (Ohab et al., 2006). In this study, with 
stereological quantification, they found around 2,000 DCX+ cells in the peri- infarct 
cortex per animal at day 3 after stroke, increasing to more than 10,000 DCX+ cells per 
animal at day 7. In the present study, the number of induced neuroblasts (DCX+cells) 
post-PVD II is much lower (estimated at around 150 DCX+ cells in the injured 
neocortex per animal) as compared to the number of DCX-expressing cells in the study 
by Ohab (2006). In that study, the focal ischemic injury was induced by permanent 
occlusion of the distal middle cerebral artery and transient occlusion of the bilateral 
common carotid in the mouse, and was mainly located at the somatosensory barrel field 
cortex (Ohab et al., 2006). As mentioned before, the PVD II model induces a smaller 
cortical ischemic injury as compared to other cortical ischemic models and the lesion is 
mainly located in the primary motor cortex. Taking these data together, it is highly likely 
that the nature of the injury, the location and extent/size of the ischemic injury may 
influence the degree of the signal(s) necessary to recruit migration of neuroblasts and 
induce neuronal subtype differentiation. Indeed, it has been shown that the number of 
the immature neurons and newly generated neurons in the striatum correlated 
significantly with the volume of the striatal injury (Thored et al., 2006).  
This study did not attempt to determine the long-term survival of these 
DCX-expressing neuroblasts. Therefore the ultimate fate of these DCX+ cells is unclear. 
Long-term survival studies suggest that the majority of the newly generated neuroblasts 
in the damaged area undergo programmed cell death, while a small portion survive for 
many months, differentiate into neurons expressing mature neuron markers and regional 
specific neuron markers (Arvidsson et al., 2002; Ohab et al., 2006; Thored et al., 2006), 
and form synapses in the damaged area (Yamashita et al., 2006). This is an indication 
that these cells may be functional mature neurons. However, functional analysis, such as 
the use of electrophysiology to determine the neuronal properties of these newborn 
neurons was not undertaken.  
The appearance of DCX+ cells in the neocortex and corpus callosum of adult rats 
after a cortical ischemic injury raises the question of the cellular origin of these induced 
DCX+ neuroblasts. Do they arise from local parenchymal precursors or precursors from 
normally neurogenic regions, such as SVZ, which might migrate long distances into the 
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injured neocortex in response to the ischemic stimulus? By directly labeling SVZ cells 
with DiI or a viral vector, SVZ neuroblasts have been shown to migrate into the 
damaged striatum and/or cortex in response to ischemic injury (Jin et al., 2003; Ohab et 
al., 2006; Yamashita et al., 2006) and traumatic injury (Ramaswamy et al., 2005). After 
PVD II, DCX + cells mainly located in both the neocortex and corpus callosum between 
the injury and SVZ area. These DCX+ cells display a differential morphology. It seems 
that in the white matter, DCX+ cells display the form typical of migrating neuroblasts, 
i.e. elongated nuclei with leading processes (Nacher et al., 2001; Brown et al., 2003). In 
the neocortex, DCX+ cells have a morphology more like a differentiated cell: a more 
rounded cell body with long and branched processes (Nacher et al., 2001). Time course 
quantification of DCX+ cells showed that the stroke-like injury first induced a peak of 
DCX+ cells in the subcortical white matter, and then in the peri- infarct cortex. These 
results suggest that these DCX+ cells migrate from the direction of the corpus callosum 
to the neocortex. However, the orientation of these DCX+ cells was not necessarily 
consistent with migration away from the corpus callosum toward the ischemic injury. I 
hypothesized that these DCX+ cells are originating from the SVZ precursor cells, the 
biggest neural progenitor pool of the adult brain. In response to PVD II, the SVZ 
neuroblasts may migrate out of the RMS, through the corpus callosum into the neocortex 
towards the lesion. However, in vivo labeling of SVZ cells with CFSE resulted in no 
CFSE-labeled cells outside the SVZ-RMS-OB pathway. This suggests that these DCX+ 
cells are not originally from the subventricular zone of the lateral ventricle. One possible 
source is that precursor cells might be residing in the corpus callosum. Studies suggest 
that OPCs may possess a wider differentiation potential than previously assumed and 
thus may be considered a multipotent stem cell (Kondo and Raff, 2000; Belachew et al., 
2003). Resident glial precursors isolated from human subcortical white matter appear to 
be multipotential cells that are capable of undergoing not only gliogenesis but also 
neurogenesis in vitro, and following transplantation in vivo (Nunes et al., 2003). 
Following transplantation to the adult rat hippocampus, cortical OPCs differentiated into 
cells expressing DCX and NeuN (Gaughwin et al., 2006). Although I was not able to 
show that these DCX cells coexpressed glial antigen 2 (NG2), a marker for OPCs, it 
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could very well be that these OPCs lost the expression of NG2 as they began 
differentiating into the neuronal lineage cells.  
Another possible source is bone marrow-derived cells. It has been reported that 
migrating neuroblasts cluster in the peri- infarct area in the vicinity of blood vessels 
(Zhang et al., 2001; Thored et al., 2006; Yamashita et al., 2006). This close association 
suggests that these cells were recruited either from local multipotent precursors cells, or 
from the infiltration of blood-borne cells (Lledo et al., 2006). Bone marrow contains a 
wide variety of stem and progenitor cells, such as hematopoietic stem cells, that can 
mobilize into ischemic sites (Rafii and Lyden, 2003). After cerebral ischemia, bone 
marrow-derived cells rapidly infiltrate the brain. There they give rise primarily to 
microglia and endothelial cells. There are also reports that they give rise to a limited 
number of cells with neuronal markers (Hess et al., 2002; Cogle et al., 2004; Hess et al., 
2004).  In the present study, injections of 200 nl CFSE into the SVZa resulted in no 
labeling of the contralateral lateral ventricle, which suggests that by using this injection 
method, CFSE was not transported with the bulk flow of cerebral spinal fluid as shown 
by some authors (Ramaswamy et al., 2005). Therefore, CFSE should not be able to label 
any blood born cells in this study. If these DCX+ cells indeed arise from bone 
marrow-derived cells, this CFSE-labeling method would not result in the appearance of 
labeled cells in the peri- infarct area.  
Recent studies using transgenic targeting strategies (Cre- loxP recombination 
system) to specifically label SVZ cells, have provided direct evidence that stroke can 
induce the migration of SVZ neuroblasts into the damaged striatum (Yamashita et al., 
2006) and cortex (Ohab et al., 2006). The GFAP-expressing cells are the primary 
progenitors of these migrating neuroblasts, although it can not be ruled out that some of 
the newborn neurons may be generated locally. I n  a study of the fates of newborn 
neurons in an induced synchronous apoptotic degeneration model of corticothalamic 
projection neurons, it was suggested, but not proven, that newborn neurons appear to 
originate from precursors located within the neocortex. A second population appeared to 
originate in or near the subventricular zone (Magavi et al., 2000). In the present study, as 
suggested by the number of DCX+ cells, the number of migrating neuroblasts/immature 
neurons after PVD II are fairly low and this makes it difficult to study the origin and 
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precise phenotypes of these cells. The low level of cortical neuroblasts i n  these 
experiments as compared to other studies (Ohab et al., 2006; Yamashita et al., 2006) 
could be caused by the large ischemic lesion in the striatum and/or cortex, which may 
attract new neurons formed in the SVZ more efficiently, as compared with the small 
distant cortical lesion produced in this study. It is also important to underscore that the 
approaches used in this study to trace SVZ cells have detection limits. As a lipophilic 
dye, CFSE may be diluted over time by cell divisions. As well, the one-time injection of 
CFSE into SVZ may only label a portion of the SVZ cells. Therefore I can not rule out 
the possibility that there is a very small stream of neuroblasts that migrate out of the 
RMS in response to cortical ischemic injury. If these DCX+ cells are indeed derived by 
migration from the SVZ, the tracing of such a low number of cells can only be achieved 
by genetically tagging all the SVZ neural progenitors.  
Stroke is a leading cause of death and disability and it is a diverse disease in 
terms of causes, manifestations, severity and anatomic sites. In response to PVD II, a 
model mimicking small vessel stroke, DCX+ neuroblasts appear in the neocortex and 
corpus callosum of adult rats up to 14 days post injury. These results demonstrate that 
endogenous neural precursors can be induced to differentiate into neocortical neuronal 
lineage cells in the neocortex, a non-neurogenic region of the adult rodent brain. 
Regeneration of the lost neurons is critical for functional improvement. These results 
suggest that progenitor cells of the rodent adult brain can be triggered to produce new 
cortical neurons in response to  small vessel stroke, although this neurogenic response 
might be low and transient. This opens up the possibility of a therapeutic approach to 
enhance the generation and survival of these new neurons and their incorporation into 
reorganizing neural circuits. A precise understanding of the mechanism of neuronal 
regeneration is necessary in order to design novel strategies to enhance these processes. 
In vivo labeling of SVZ cells with CFSE resulted in no CFSE labeled cells outside the 
SVZ-RMS-OB pathway. This finding does not support the notion that these DCX+ cells 
are neuroblasts migrating from the subventricular zone of the lateral ventricle. An 
alternative is that they might be derived from local precursors, either from the corpus 
callosum or the neocortex itself. However, the number of induced neuroblasts (DCX+ 
cells) post- injury is low. Therefore, it is possible that there is indeed a very small stream 
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of neuroblasts migrating out of the RMS in response to the cortical injury, as this may 
not be detected by the current in vivo SVZ cell- labeling technique. 
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8. GENERAL DISCUSSION 
8.1 PVD II, a Model to Mimic Small Vessel Stroke 
 
Stroke is a disease caused by blood vessel dysfunction. It is the third leading 
cause of death in North America (Fatahzadeh and Glick, 2006). To date, most 
commonly used stroke models involve the occlusion of larger arteries and induce 
massive lesions (Carmichael, 2005). However, approximately 25% of first human 
strokes are caused by small vessel ischemia (Lammie et al., 1998; Greenberg, 2006). In 
Japan, over 50% of ischemic strokes are the result of small vessel ischemia (Greenberg, 
2006; Kitamura et al., 2006) and they are also more common in China than in the 
western countries (Davis et al., 1990). It is now generally acknowledged that small 
vessel ischemia can eventually lead to lacunar infarctions (Lammie, 2000). However, 
stroke based on small-vessel disease has been underrepresented in stroke models. There 
are no satisfactory animal models for lacunar infarction, which would allow for 
systematic study of the genesis and properties of lacunes. Consequently small vessel 
disease and resulting lacunar infarction have not been well studied in experimental 
models (Greenberg, 2006). 
The original pial vessel disruption model involves the stripping of all vessels in 
an area of the cortex. This results in a large rectangular lesion involving subcortical 
structures, such as corpus callosum, and also creates hemorrhage (Farr and Wishaw, 
2002; Gonzalez and Kolb, 2003).  I t  therefore resembles more a situation caused by 
neurotrauma rather than ischemia. In this thesis, this model is modified by focusing on a 
smaller surface area (5 mm diameter circle) and disrupting only medium size vessels. 
This modification prevents hemorrha g e  a n d  results in a  highly consistent and 
reproducible cortical injury, cone-shaped and exclusively located in the cerebral cortex. 
In  
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comparison with other cortical ischemic injury models, the lesion induced by PVD II is 
much smaller in size (around 1 mm3). In the third week a cavity develops in the area of 
the lesion, devoid of cells and surrounded by a glia limitans consisting of reactive 
astrocytes. The PVD II model resembles human lacunar infarctions in size and structure, 
as fluid-filled cavities are a hallmark of human lacunar infarction (Wardlaw, 2004).  
There are, however, two disadvantages associated with this model. First, the 
disruption of the vessels is irreversible. However, reperfusion is not an issue in the 
genesis and pathology of lacunar infarctions. The second and more serious problem of 
course is that this cavity is located in the gray matter of the cerebral cortex. Human 
lacunes are only in exceptional cases located in this brain area and are most commonly 
found in the deep subcortical areas, such as the putamen, caudate, thalamus and pons. 
However, they do occur occasionally in the cerebral cortex (Chester et al., 1978), 
making it likely that the same general mechanisms may apply to the genesis and 
properties of these cavities in the cerebral cortex as they would in those situated in 
deeper layers. This must be verified in the future.  
The advantages of this easy-to-use model, its reliability and reproducibility, even 
when used by different investigators, far outweigh these disadvantages, at least at this 
stage of investigation. Thus, one may be confident that the cone-shaped lesion with a 
volume of approximately 1-mm3, which turns into a fluid-filled cavity in the third week 
(Wang and Walz, 2003) is a realistic approximation of human small-vessel disease. 
8.2 Minocycline  
The search for potential therapeutic approaches for the treatment of stroke, led to 
the investigati o n  o f  two potential mechanisms: reduction of inflammation with 
minocycline treatment and neurogenesis of endogenous progenitor cells.  Minocycline 
has neuroprotective properties in different animal models of acute CNS injury and 
chronic neurological diseases due to its anti- inflammatory and anti-apoptotic actions  
(Domercq and Matute, 2004; Stirling et al., 2005).  In the present study, minocycline 
treatment was started after the induction of PVD II and continued for six days.  I t  
prevented the genesis of a cavity. With minocycline treatment the lesion volume is not 
changed, but the area that normally consists of the cavity and the surrounding glia 
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limitans is now not separated from the parenchyma by a wall (the glia limitans), but 
remains part of the parenchyma. It is completely filled with reactive astrocytes. 
Progressive cavitation is closely related to the inflammatory response and is based on 
activation of microglia/macrophages and migration of reactive astrocytes out of the 
affected area (Fitch et al., 1999). This leads to abandonment by astrocytes and therefore 
leaves this area more vulnerable to inflammatory damage. Therefore, it may not come as 
a surprise that this process is a natural target for minocycline as minocycline is generally 
assumed to interfere with inflammation and microglial properties. In the PVD II, it was 
found that shortly after injury, the PMNs were recruited and infiltrated in the lesion area, 
followed by delayed infiltration of T cells and activated microglia / macrophages (both 
of hematopoietic origin and brain microglia) in the ischemic area and boundary zone. 
Six days after lesioning, an astrocytic boundary, known as glia limitans, started to form 
around the lesion. The formation of this border must be prevented by minocycline. 
Therefore reactive astrocytes can migrate back into the lesioned area and this migration 
prevented the formation of a f l u i d -filled cyst. It is usually persistent 
macrophage/microglia activation that  is responsible for the outward migration of 
astrocytes first of all (Fitch et al., 1999). Activated microglia/macrophages not only act 
as scavengers removing tissue debris, but also release numerous agents that are toxic to 
CNS cells, including inflammatory cytokines and glutamate, which aggravate secondary 
tissue injury and modulate the astrocyte response by releasing inflammatory cytokines, 
such as IL-1β and chemoattractants, such as osteopontin and MMPs. Although no direct 
evidence for reduced inflammation after minocycline treatment was found in this study, 
it seems most likely that minocycline is preventing cavitation through its 
anti- inflammatory effect on microglia early during the first 6 days.  
8.3 Appearance o f  Cortical Neuroblasts in Response to the 
PVD II Model 
I investigated if, in response to PVD II, there is an induction of neurogenesis by 
endogenous precursors, which could potentially be harnessed for post-stroke treatment. 
In response to this injury, DCX-expressing neuroblasts were present in the neocortex 
and corpus callosum underneath the lesion up to 14 days after injury. Using both 
 111 
morphological and immunocytochemical criteria, I  a m  conf ident that these 
DCX-expressing cells are migrating neuroblasts/immature neurons and that they are 
present in the ischemic neocortex, a non-neurogenetic area in the normal adult brain. As 
I found no evidence for a migratory route out of the SVZ-RMS-OB axis towards the 
lesioned cerebral cortex, it seems likely that these cells are generated locally in the 
cerebral cortex. T herefore these results support the view that the adult cortex is capable 
of neuronal regeneration in response to ischemic injury. This evidence of neurogenic 
upregulation in the damaged ischemic brain is of potential interest for the development 
of therapeutic strategies that exploit naturally existing responses. However, it  i s  
important for me to remain critical and cautious in the interpretation of the phenomenon 
of post-stroke cortical neurogenesis. In this thesis, no experiments with regard to the fate 
of these DCX+ cells were performed, and therefore there is no evidence that these 
DCX+ cells in the neocortex survive and become functional mature neurons after PVD 
II. However, these results do suggest that it may be possible to manipulate endogenous 
neural precursors in situ to undergo neurogenesis in the adult brain. Whether this 
endogenous post-stroke neurogenesis can improve functional recovery after stroke is 
unresolved. Attempts at endogenous repair might require exogenous support to increase 
the number of neurons generated in the injured area. Elucidation of relevant molecular 
targets is necessary for the development of future neuronal replacement therapy after a 
stroke that does not require transplantation of exogenous cells.  
8.4 The Origin of the Induced Cortical Neuroblasts 
In this study, in vivo labeling of SVZ cells with CFSE did not result in the 
appearance of any CFSE-labeled cells outside the SVZ-RMS-OB axis in response to 
PVD II. This finding does therefore not support the view that these DCX+ neuroblasts 
migrated from the SVZ o f  the lateral ventricle in response to the ischemic injury. 
However, due to the technical limitations, I can not completely rule out such a 
conclusion unless the method used for tracing migration would result in the permanent 
labeling of all the SVZ cells and their progeny. Doing this by taking advantage of the 
Cre-loxP system in transgenic mice, which resulted in region- and cell- type-specific cell 
labeling and long-term tracing of SVZ cells, recent studies (Ohab et al., 2006; 
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Yamashita et al., 2006) have shown that SVZ GFAP-expressing precursor cells are the 
primary source of new neurons in the ischemic brain. It would be interesting to apply the 
PVD II model to these Cre-transgenetic mice. This may help to elucidate the origin of 
the DCX+ neuroblasts. The other possible origin of these DCX + neuroblasts i n  the 
present study could be the local parenchymal precursors of the corpus callosum or  
cerebral cortex. Multipotent neural progenitors have now been isolated from various 
non-neurogenic regions of the adult mammalian CNS (reviewed in section 1.3.2.1.3). 
Resident glial precursors isolated from human subcortical white matter appear to be 
multipotential cells capable of undergoing gliogenesis as well as neurogenesis in vitro 
following transplantation (Nunes et al., 2003). Intraventricular infusion of specific 
growth factors, such as EGF, an effective mitogen, may help to elucidate the cell origin. 
When growth factors are infused into the lateral ventricle, they do not diffuse very far 
into the parenchyma of the brain. Therefore, their first molecular targets ha ve to be 
neural precursors in the SVZ. Thus, if such an intraventricular growth factor infusion 
affects the number of DCX+ neuroblasts after PVD II, it would provide valuable 
evidence that SVZ precursors contribute to these DCX+ cells. If intraventricular infusion 
had no effect on the numbers, it would suggest that these cells are derived from 
parenchymal precursors. Identifying the origin of these post-PVD II DCX+ neuroblasts 
would be particularly relevant to the possibility of manipulating endogenous precursors 
for therapeutic purposes. 
8.5 Future Direction 
The mammalian brain is known to have limited ability to regenerate after injury. 
The presence of DCX+ neuroblasts after a PVD II lesion raises some questions: e.g., is 
this an attempt of the brain to regenerate new cortical neurons to replace the dead ones 
induced by ischemic injury? To answer this question, it would be important to follow the 
maturation of these DCX+ cells and their ultimate fate. Further research should also 
focus on understanding the crucial signals for proliferation, survival and differentiation 
of the endogenous precursors. This may lead to development of a method to manipulate 
the low level of post-stroke neurogenesis to a therapeutically useful level.  
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Post-stroke inflammation is a complex phenomenon that involves many different 
inflammatory cells in the CNS, and plays an important role in cell survival and tissue 
remodeling. It has been suggested tha t  inflammation is detrimental to neurogenesis 
(Ekdahl et al., 2003). Blocking inflammation by minocycline has been shown to increase 
the survival of new hippocampal neurons after focal ischemia (Liu et al., 2007). On the 
other hand, it has also been reported that inflammation at the injury site plays an 
important role in attracting the neural precursor cells, which then migrate toward 
damaged areas of the brain, possibly through some chemokines (Belmadani et al., 2006). 
Therefore, it would be particularly interesting to combine the two pieces of work in this 
thesis to examine the effect of inflammation on the expression of DCX+ after PVD II 
lesion. These experiments may shed light on the therapeutic potential of 
anti- inflammatory therapy on brain repair after ischemia.  
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9. CONCLUSION 
 
In this study, a new rat stroke model was introduced, a modification of the 
original pial vessel disruption model, but with vastly different properties. It always leads 
to the development of a fluid-filled encapsulated cyst as a result of exclusive disruption 
of medium-sized vessels. I therefore make an argument that this model, albeit situated in 
the cerebral cortex, can be used to study cavitation. I also argue that this cavitation is a 
model of the genesis of lacunar infarctions. This model should therefore be useful in the 
study of the genesis of lacunes as a result of ischemia in small vessels. It should be 
useful in the development of pharmacological strategies with the aim to prevent 
formation of lacunar infarctions. 
I find evidence for inflammation as a major contributor to cavitation after PVD 
II, especially for microglia-astrocyte interaction. Minocycline interferes with these 
interactions, therefore i t  may  facilitate the repopulation of the lesion by reactive 
astrocytes and prevent formation of a cavity and a glial limitan. Although I did not find 
direct evidence for reduced inflammation at the cellular level after minocycline 
treatment, it seems likely minocyline acts on the signaling between microglia and 
reactive astrocytes.  
I found evidence that endogenous neural precursors may serve as a source of new 
neurons after small vessel strokes. In response to PVD II, cells which express DCX and 
immature neuronal markers, and exhibit the morphology  of neuroblas ts  and 
post-migrating neurons, appear in the neocortex and corpus callosum. These a re  
non-neurogenetic areas in the normal adult brain. The presence of these migrating 
neuroblasts / immature neurons, is an indication that endogenous precursors attempt to 
become neurons in the vicinity of the cortical ischemic injury. Results from these in vivo 
labeling experiments suggested that these post-stroke induced neuroblasts / immature 
neurons are not originating from the SVZ, but might be generated from local precursors  
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in the neocortex or corpus callosum. However, as the number of induced neuroblasts 
(DCX+ cells) is low, we can not rule out the possibility that these cells are indeed from 
SVZ-RMS axis and that we failed to detect this small stream of emigration due to 
limitations of our tracing technique. I tested various tracing procedures and the 
CFSE-labeling approach seemed to be suited best for the purposes of the present study. 
Taken together, I have developed a new animal model that can be used with high 
reliability and low variation to create lacunar infarction – like injuries. It therefore can 
serve as a model of small vessel disease, a highly undeveloped area of research. The 
findings that minocycline treatment after stroke prevents these lacunes and that 
neuroblasts appear near the lesion in the neocortex opens up new targets for post-stroke 
treatment.  
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